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Abstract 
 
Background: Fibromyalgia (FM) is still often viewed as a psychosomatic disorder. However, 
the increased pain sensitivity to stimuli in FM patients is not a phenomena of imagination, but 
the result of specific abnormalities in the central nervous system (CNS) pain matrix.  
Brain-derived neurotrophic factor (BDNF) is an endogenous protein involved in neuronal 
survival and synaptic plasticity of the central and peripheral nervous systems. Several lines of 
evidence converge to indicate that BDNF also participates in structural and functional 
plasticity of nociceptive pathways in the CNS and within the dorsal root ganglia and spinal 
cord. At these levels, release of BDNF appears to modulate or even mediate nociceptive 
sensory inputs and pain hypersensitivity.  
In the literature few studies evaluated BDNF levels in serum, plasma and cerebrospinal fluid 
samples of FM patients, finding increased levels of this neurotrophin compared to healthy 
controls. A number of studies also investigated BDNF levels in synovial fluid and plasma 
samples from patients affected by rheumatoid arthritis (RA), who are chronically subjected to 
pain, even though of inflammatory and autoimmune origin. No studies instead have been 
performed on patients affected by chronic fatigue syndrome (CFS), a condition that frequently 
overlaps with FM and whose etiopathogenesis, still unclear, is probably different from that of 
FM. 
Objectives: The primary objective of the present PhD thesis project was therefore to 
investigate BDNF-mediated neuroplasticity, by detecting BDNF levels in FM patients, and 
therefore by comparing these levels to the ones found in CFS, RA and healthy volunteers.  
Secondary objectives were: (i) the relation between BDNF levels and clinical variables, 
including neurocognitive disorders, which were assessed in FM and CFS patients by means of 
a computerized system; (ii) the relation between BDNF levels and psychiatric comorbidity in 
FM and CFS patients; (iii) the relation between BDNF levels and inflammatory status in RA 
patients; (iv) serum and plasmatic BDNF levels in a subgroup of FM patients before, 
immediately after, and 3-months after thermal treatments. 
Materials and methods: Among the patients recruited in the study, there were 68 FM, 45 
CFS, and 46 RA together with 40 healthy controls. BDNF serum levels were determined by 
enzyme-linked immune-sorbent assay (Promega), and the differences among the various 
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groups were observed. Demographic and clinical parameters were investigated in relation to 
BDNF levels. Moreover, a subgroup of FM patients (n=28) also participated to a clinical trial 
held at the Montecatini Thermal Baths, and another subgroup of FM patients (n=40), together 
with CFS patients, also completed a computerized test battery for the assessment of 
neurocognitive disorders.  
Results: The main findings of the work can be summarized as follows: (i) the increased 
BDNF levels in sera of patients affected by FM, CFS and RA (but only those who were 
positive to rheumatoid factor of all isotypes), compared to healthy volunteers; (ii) the positive 
correlation between BDNF and rheumatoid factor (IgG and IgM isotypes), and the negative 
one with C-reactive protein; (iii) the lack of correlation between BDNF and neurocognitive 
disorders, assessed by the software CNS Vital Signs©; (iv) the higher prevalence of 
neurocognitive disorders in FM than in CFS patients, despite the more frequent complaint of 
CFS patients; (v) the tight relationship between neurocognitive impairments and chronic pain, 
which is independent of psychiatric comorbidity.    
Conclusions: The conclusion reached by this study is that BDNF-mediated neuroplasticity in 
FM, CFS and RA could be interpreted as a protective mechanism against injuries, chronic 
pain and, more generally, against chronic stress conditions. This hypothesis could explain the 
elevated BDNF levels found in sera -but not in plasma- samples, and their decrease after 
thermal treatment. Although BDNF is not specific for FM or chronic pain -the difference here 
reported between BDNF levels of FM, CFS, RA patients compared to healthy controls are not 
strong enough to allow the use of BDNF in the diagnostic field- this work on one hand opens 
the way to new investigations on FM, CFS and RA etiopathogenesis, and on the other could 
suggest BDNF as a useful biomarker for FM/chronic pain therapy monitoring.  
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Chapter 1 
 
Introduction 
 
1. Fibromyalgia 
1.1. Definition and classification criteria 
Fibromyalgia (FM) is a common extra-articular rheumatic syndrome characterized by 
chronic musculoskeletal widespread pain and presence of multiple points tenderness to 
palpation (tender points). Muscle pain is typically aggravated by inactivity or exposure to 
cold. This condition is often associated with general symptoms, such as fatigue -particularly 
post-exertional fatigue not resolved by rest-, sleep disorders, stiffness, headaches, affective 
and neurocognitive disorders, which can appear together with a plethora of other symptoms, 
particularly of neurovegetative origin. Fibromyalgia may arise as a primary or secondary 
disease process. It is most frequent in females aged 20 to 50 years (Adams et al.,1997).  
FM is considered a severe subtype of a condition termed chronic widespread pain (Croft P 
et al, 1996; Croft P., 2000), which is also characterized by generalized pain, but without the 
additional requirement of tender points. People with FM and chronic widespread pain 
experience poor subjective health, fatigue, sleep disorder, and physical impairments (Aaron 
LA and Buchwald D, 2003; Prescott E et al, 1993). 
The American College of Rheumatology (ACR) classification criteria drawn up in 1990 
has been used for decades. According to it, the diagnosis of fibromyalgia required tenderness 
on pressure in at least 11 of 18 specified sites and the presence of widespread pain, defined as 
axial pain, left and right-sided pain, and upper and lower segment pain (Wolfe F et al, 1990). 
However, in the last years, many objections have been expressed in relation to ACR 1990 
criteria, particularly because they stipulated that, in order to make a diagnosis of fibromyalgia, 
chronic widespread pain should be present for at least 3 months, without specifying that any 
other disease, accounting for the chronic widespread pain, had to be excluded by the 
examiner. Furthermore, tender point count was rarely or incorrectly performed in primary 
care and the importance of symptoms was not considered. Indeed patients whose symptoms 
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and tender points decreased often failed to satisfy these criteria: approximately 25% of FM 
patients did not satisfy the ACR 1990 classification criteria although they were considered by 
their physicians to suffer from this condition.  
The previous objections, together with the real need to find a common definition and 
classification for FM, in 2010 led Wolfe and colleagues (Wolfe F et al, 2010) to develop 
simple, practical criteria for clinical diagnosis of fibromyalgia. These new criteria had been 
thought to be suitable for use in primary and specialty care and did not require a tender point 
examination, providing instead a severity scale for characteristic fibromyalgia symptoms.  
The authors identified two variables that best defined fibromyalgia and its symptom spectrum: 
the widespread pain index and the composite symptom severity scale, a composite variable 
composed of physician-rated cognitive problems, unrefreshing sleep, fatigue and somatic 
symptoms.  
Furthermore in 2011 Wolfe published a modification of the ACR preliminary Diagnostic 
Criteria for Fibromyalgia, which allowed their use in epidemiologic and clinical studies 
without the requirement for an examiner. Practically, the author modified the symptom 
severity scale by substituting for the somatic symptoms item a 0-3 item that represented the 
sum of 3 items: headaches, pain or cramps in liver abdomen or depression symptoms during 
the previous 6 months. However, it is important to remark that, although simple to use, the 
new criteria are not thought to be used for self-diagnosis (Wolfe F et al, 2011). The presence 
of diagnostic criteria based only on clinical evidence let us understand that any objective 
diagnostic biomarker has not been jet discovered. 
1.2. Epidemiology 
Fibromyalgia has a different prevalence depending on the population studied and the 
criteria used, oscillating from 0.7% to 20% (Wolfe F et al, 1995). Most FM patients are 
middle-aged women (73-88%). However it has also been described in children
 
(Yunus MB 
and Masi AT, 1985), as well as in the elderly
 
(Yunus MB et al, 1988). In a rheumatology unit, 
about 10-20% of the patients suffer FM, a proportion that descends to 2.1-5.7% in non-
specialized clinics (Wolfe F et al, 1995; Wolfe F, 1989). In a large cohort of Spanish patients 
the prevalence of FM in the adult population is estimated at 2.37% (95% CI: 1.53-3.21). 
Eighty to 90% of fibromyalgia suffers are women (Mas AJ et al, 2008). 
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1.3. Comorbidities and/or overlapping conditions 
Fibromyalgia frequently occurs together with other conditions. Indeed it can be secondary 
to other rheumatic diseases, such as Rheumatoid Arthritis (RA) (Yunus MB, 2012), Sjögren 
Syndrome (Priori R et al, 2010) and Systemic Lupus Erythematosus (Yunus MB, 2012), or to 
coexists with other syndromes and disorders, particularly chronic fatigue syndrome (CFS) 
(Aaron LA et al, 2000; Hollins M et al, 2011), temporomandibular disorder (Aaron LA et al, 
2000), restless leg syndrome (Viola-Saltzman M et al, 2010), irritable bowel syndrome and 
diabetic neuropathic pain (Koroschetz J, et al 2011). 
However, the most frequently FM-associated conditions are probably represented by RA 
and CFS, which will be described in paragraphs 2 and 3. 
1.4. Etiology 
The etiology of FM has not yet been fully understood. Several researchers (Kindler LL et 
al, 2011; Yunus MB, 2008; Coderre, TJ et al, 1993; Nielsen LA and Henriksson KG, 2007, 
and other authors) agree on the role of central sensitization as a mechanism of hyperalgesia 
induction, but unfortunately the mechanism by which the sensitization occurs is less clear. As 
noted, central sensitization is due to ongoing C-fiber stimulation, or painful input, resulting in 
sustained increases in the excitability and responsiveness of neurons in the spinal cord 
(Zusman M, 2002). While pain processing abnormalities, such as deficient endogenous pain 
inhibition (Julien N et al, 2005), have been proposed to enhance the intensity of nociception 
in patients with FM, research is less clear on the mechanism generating the ongoing 
nociceptive input needed to initiate central sensitization (Vierck JCJ, 2006). During the last 
two decades, a plethora of etiologic causes for fibromyalgia have been explored. The 
hypotheses generally more accepted are based on the following triggering factors: local 
chronic pain, genetic polymorphisms, infectious agents, autonomic nervous system (ANS) 
dysfunction, distress and traumatic events.  
1.4.1. Hypothesis of local chronic pain  
One of the more accredited hypotheses is that regional or focal chronic pain might produce 
the sustained noxious input that results in hypersensitivity of the central nervous system 
(Bennett R, 2005; Lidbeck J, 2002; Staud R, 2007). This hypothesis proposes that 
longstanding bombardment of spinal cord neurons by A-beta and C fibers, resulting from 
ongoing focal pain conditions, gives rise to the neuroplastic changes characteristic of central 
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sensitization (Meeus M and Nijs J 2007; Nielsen LA and Henriksson KG 2007), making 
regional pain conditions a possible instigator for the altered pain processing of FM. In fact, it 
has been proposed that regional pain syndromes precede the development of widespread pain 
in most patients with FM (Nielsen LA and Henriksson KG 2007). This proposal is supported 
by the fact that FM is frequently associated with several focal pain conditions that also have 
evidence of being characterized by altered pain processing, including TMD, IBS, IC, 
headaches, back pain, and neck pain (Staud R, 2007). These peripheral pain generators could 
provide the necessary tonic nociceptive input that leads to abnormal pain processing within 
the CNS. Indeed, generalized hyperalgesia has been confirmed in several of these disorders 
(Kindler LL et al, 2011).  
1.4.2. Genetic hypothesis  
Another frequently supported hypothesis is the genetic one. Indeed, about one-third of 
patients with FM have a close relative who is similarly affected and this relative is usually a 
woman. A family member of a patient with FM is about 8 times more likely to develop FM, 
compared to a family member of a patient with RA. It is reasonable, therefore, to predict that 
genetic predisposition to or more biochemical dysfunctions may be important to the 
development and/or perpetuation of FM (Xiao Y et al, 2011). Genetic associations with FM 
have been sought with polymorphisms of enzymes, receptors and transporters, as recently 
reviewed (Bazzichi L et al, 2010). However, most of the identified associations have not been 
confirmed and few if any have been linked to a relevant biological function marker (Blanco I 
et al, 2010; Ablin JN et al, 2009).  
One of this rare marker is represented by COMT polymorphisms. The enzyme COMT 
catalyses methylation, which is the major metabolic transformation of catecholamines that 
occurs throughout the body. The COMT gene has abundant functional polymorphisms, 
among which the better known transition occurs in codon 158. Indeed, the val/val genotype 
gives rise to an effective enzyme whereas the met/met genotype produces a “lazy” enzyme 
unable to effectively clear catecholamines from the system (Zubieta JK et al, 2003). Indeed 
two studies showed that subjects with FM less frequently have the val-158-val genotype of 
the COMT gene when compared with healthy control individuals, suggesting that females that 
do not degrade catecholamines properly have higher risk to develop FM (Gursoy S et al, 
2003; Garcia-Fructuoso FR, 2006). Moreover, another research found other frequent 
polymorphisms, in linkage disequilibrium with the val-158-met transition, that induce an even 
more defective enzyme. It has been shown that a particular COMT gene haplotype named 
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HPS gives rise to a 11 times less efficient enzyme, which is interestingly associated with high 
pain sensitivity in healthy females (Diatchenko L et al, 2005). 
In a recently published genetic study, a large scale candidate gene approach was used to 
evaluate over 350 genes known to be involved in nociception, inflammation, and affection 
(Smith SB et al, 2012). Several unsuspected genes, differed in frequency between FM patients 
and healthy controls, although none of the previously found gene polymorphisms have been 
found (Bazzichi L et al, 2010).  
Of particular interest is the association of the GRIA4 polymorphism with FM, which seemed 
to involve central sensitization mechanisms, providing a further proof of what have been 
speculated in the previous paragraphs. Indeed GRIA4 encodes the AMPA-sensitive, 
ionotropic glutamate receptor subunit GluR4, which mediates fast excitatory transmission of 
nociceptive signals in the CNS. Moreover, spinal AMPA receptors have also been implicated 
in the production of visceral hyperalgesia. Collectively, these observations suggest that 
alterations in AMPA receptors are likely to contribute to the complex signs, symptoms, and 
comorbidities associated with FM (Smith SB et al, 2012) (Figure 1). 
1.4.3. Infectious hypothesis 
It has been proposed that fibromyalgia syndrome could occur after an opportunistic 
infection, but results from the literature are not consistent (Ablin JN et al, 2006). Recently it 
has been reported that FM patients had higher levels of serum helicobacter pylori IgG than 
healthy controls (Akkaya N et al, 2011), but this was immediately followed by a comment 
highlighting its limits, which made results appearing unreliable (Zavos C et al,  2011). 
1.4.4. Autonomic nervous system dysfunction hypothesis: FM in relation to stress 
and traumatic events 
Living organisms survive by maintaining harmonious equilibrium or homeostasis. Stress 
can be defined as a state of disharmony, or threatened homeostasis. For human beings a 
stressor could have a psychological origin (ongoing anger, anxiety, or depression) but can also 
originate from a biological insult (an infection, a burn, or a myocardial infarction). The term 
stress or stressor should therefore not be restricted to psychological events but should be 
rather viewed in an ample physiological context (Martinez-Lavin M, 2007).  
The Autonomous Nervous System (ANS) may be viewed as the interface between mind 
and body functions, the main regulatory system of the body in charge of maintaining essential 
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involuntary functions, such as the so called vital signs (blood pressure, pulse, respiration, and 
temperature). The ANS balances the function of all internal organs, with the heart rate, 
intestinal motility, urination, and sexual activity, among many other variables, all regulated by 
the system. It is activated by centers located in the spinal cord, brain stem hypothalamus, and 
thalamus. These centers also receive input from the limbic area and other higher brain 
regions. Emotions (fear, anger, and panic) have therefore immediate biological responses 
(pupil dilation, paleness, and tachycardia). The peripheral autonomic system is divided into 
two branches; sympathetic and parasympathetic. These two divisions have antagonistic 
actions on most bodily functions and thus their proper balance preserves homeostasis. The 
action of these two branches is mediated by three neurotransmitters named catecholamines: 
norepinephrine, epinephrine, and dopamine. 
For many years it has been assumed that abnormal activity of the sympathetic nervous 
system may be involved in the pathogenesis of chronic pain syndromes. This assumption was 
based mainly upon the evidence that pain is spatially correlated with signs of autonomic 
dysfunction, with the fact that blocking the efferent sympathetic supply to the affected region 
relieves the pain, and with the observation that norepinephrine injections rekindle the pain. 
The sympathetically maintained pain concept has strong and ample foundations in the animal 
model. In contrast, the clinical information sustaining this pathogenesis is mostly anecdotal 
and does not, in most instances, fulfill the strict evidence-based medicine criteria (Martinez-
Lavin M, 2004). 
The defining FM features (widespread pain plus positivity to tender points examination), 
as well as the paresthesias these patients suffer from, could theoretically be explained by the 
pathogenetic mechanism known as “sympathetically maintained pain”. This type of 
neuropathic pain is frequently characterized by a post-traumatic onset and by the presence of 
stimuli-independent pain perception accompanied by paresthesias and allodynia (Martinez-
Lavin M, 2004), which are precisely FM pain features. Different controlled studies have 
determined that subjects with FM have higher rates of physical or emotional trauma prior to 
the onset of their symptoms (Buskila D and Neumann L, 2000). FM is clearly a stimulus-
independent pain state since there is no underlying structural damage and inflammatory signs 
are conspicuously absent. 
Several groups of investigators have defined that the typical FM tender points reflect a 
state of generalized allodynia (Russell J, 1998). Additional arguments that favor the 
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involvement of the sympathetic nervous system in the genesis of FM pain are the reports 
describing such pain as appearing submissive to sympatholytic maneuvers and to be rekindled 
by norepinephrine injections (Martínez-Lavín M et al, 2002). Moreover, as mentioned in 
paragraph 1.4.2, also genetic studies investigating COMT polymorphisms gave proof of the 
sympathetic system involvement in FM (Gursoy S et al, 2003; Garcia-Fructuoso FR et al, 
2006).  
The role of central and peripheral-stress induced sensitization in the development of FM 
symptoms is confirmed by pre-clinical studies. Recently, Green et al. (Green PG et al, 2011) 
tested the hypothesis that a rat model of fibromyalgia syndrome, sound stress-induced and at 
delayed onset, enhanced musculoskeletal and cutaneous mechanical hyperalgesia. Moreover 
through this model they were able to demonstrate the development of other important FM 
features, such as comorbidity with irritable bowel syndrome (as indicated by presence of 
gastrointestinal hypersensitivity), increased anxiety (as indicated by increased Anxiety Index 
in the elevated plus maze test) and comorbidity with temporomandibular disorder, indicated 
by hyperalgesia in the masseter muscle.  
Thus the conclusion is that an established association between stress and FM could be 
supported considering the following assertions: (i) acute stress can induce long-term changes 
in pain sensitivity with delayed onset (e.g., following a motor vehicle accident); (ii) response 
to acute stress is both the strongest predictor of maintenance of pain symptoms weeks later 
and increased pain symptoms at a later date in individuals with fibromyalgia and other forms 
of chronic widespread pain (Green PG et al, 2011). 
 
 
Figure 1 Theoretical etiopathogenetic mechanisms in fibromyalgia 
(modified from Martinez-Lavin M, 2007). 
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1.5. Pathogenetic mechanisms 
In 2011 Kindler and colleagues reviewed the scientific literature concerning the 
etiopathogenesis of FM, then describing the more accredited pathophysiologic mechanisms 
underlining chronic pain and hyperalgesia conditions. According to the authors, it is firmly 
established by now that persistent pain may lead to neuroplastic changes within the peripheral 
and central nervous system (CNS).  
As originally observed in animals, that repetitive C-fiber stimulation exponentially 
increases dorsal horn stimulation, so that the same level of stimulus produces a progressive 
increase in activation of second order neurons projecting to the brain (Mendell LM, 1966; 
Yunus MB, 2008). This phenomenon, termed windup, represents one major mechanism 
through which ongoing pain produces a hyperexcitable state within the CNS. When the 
windup occurs, pain impulses originating in peripheral nerve endings –better known as 
nociceptors- activate both Aδ and C-nociceptive fibers; these are the nerve fibers that carry 
the nociceptive impulse to dorsal horn neurons in the spinal cord. It is of great importance to 
underline that some of these neurons are multimodal and respond to the sensations of touch, 
pressure, temperature, and pain and are therefore called wide dynamic range (WDR) neurons. 
Particularly, when pain is chronic, it causes a persistent activation of Aδ and C fibers, 
stimulating the release of neurotransmitters and neuromodulators (i.e., substance P, nerve 
growth factor, brain-derived neurotrophic factor, calcitonin gene - related peptide, 
glutamate, and aspartate) into the dorsal horn synapse (Urban MO and Gebhart GF, 1999). 
Influx of these neurochemicals sensitizes the WDR neurons so that they become 
hyperexcitable, responding to lower levels of nociceptive stimuli (i.e., hyperalgesia) as well as 
some previously non-painful stimuli (i.e., allodynia) (Eide PK, 2000).  
Another important mechanism through which central sensitization modulates the 
expression of hyperalgesia is represented by the expansion of receptive fields. This occurs as 
a result of prolonged excitation of WDR neurons, which in turn activates adjacent neurons, 
thus expanding their receptive fields beyond the site of the original injury. Clinically, this 
results in pain being experienced by stimulation of locations that had not previously provoked 
a pain response (Coderre TJ, 1993; Nielsen LA and Henriksson KG, 2007). 
Although researches on the development of chronic pain states and hyperalgesia has 
traditionally focused on transmission of pain through ascending pathways (from the periphery 
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to spinal and supraspinal centers), a growing number of studies is now expanding the 
knowledge about the descending influences on the generation and maintenance of 
sensitization (Heinricher MM et al, 2009; Tracey I and Dunckley P, 2004; Kindler LL  et al, 
2011) (Figure 2).  
Concerning studies on fibromyalgia, central sensitization and impaired descending pain 
modulation are generally accepted as the two major underlying mechanisms causing 
widespread hypersensitivity to pain (Perrot S, et al, 2008; Staud R and Rodriguez ME, 2006). 
Attributes of FM that support the role of central sensitization include: (i) decreased pain 
thresholds and enhanced sensitivity outside of typical tender point locations, (ii) expansion of 
pain receptive fields, (iii) increased levels of substance P and neurotrophic factors in the 
cerebral spinal fluid, (iv) abnormal windup, and (v) prolonged pain after cessation of painful 
input (Dadabhoy D et al, 2008; Giovengo SL et al, 1999).  
FM patients who were subjected to a cold pressor test showed lower pain threshold and 
tolerance (i), as well as higher ratings of pain intensity and unpleasantness on visual analogue 
scales, as reported by Reyes del Paso et al. (Reyes del Paso GA et al, 2011). Moreover, data 
from this study suggest impaired autonomic cardiovascular regulation in FM in terms of 
reduced sympathetic and parasympathetic influences, as well as blunted sympathetic 
reactivity to acute stress. The association between baroreflex function and pain experience 
reflects the pain inhibition mediated by the baroreceptor system. Given this reduced 
baroreflex sensitivity in FM, the authors hypnotized that deficient ascending pain inhibition 
could arise from the cardiovascular system, which may contribute to the exaggerated pain 
sensitivity of FM.  
The expansion of receptive fields (ii) is an important mechanism through which central 
sensitization modulates the expression of hyperalgesia. This occurs as a result of prolonged 
excitation of WDR neurons, which in turn activates adjacent neurons, thus expanding their 
receptive fields beyond the site of the original injury. Clinically, this results in pain being 
experienced by stimulation of locations that had not previously provoked a pain response. 
As for point (iii), substance P, along with excitatory amino acids, such as glutamate (Harris 
RE, 2010) and aspartate, is known to enhance the transmission of pain through the primary 
afferent neurons (Larson AA et al, 2000). A study demonstrated that substance P levels in FM 
patients are two- to threefold that of healthy controls (Russell IJ, 1998; Russell IJ and Bieber 
CS, 2006). Increased levels of substance P can induce hyperalgesia and allodynia by lowering 
the firing threshold of spinal cord neurons and extend long distances from the pain locus, 
resulting in sensitization at sites distant from the pain locus (Bennett RM, 1999). Moreover, 
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the combination of elevated glutamate and substance P and reduced serotonin supports a 
role for central amplification in the abnormal pain transmission and perception of patients 
with FM. In fact, in these patients cerebrospinal fluid (CSF) levels of NGF and BDNF were 
founded increased compared to healthy non-painful controls (Giovengo et al SL, 1999; Laske 
C et al, 2007; Sarchielli P et al, 2007), and correlated with increased glutamate levels. The 
authors speculated that NGF probably acts indirectly to increase BDNF expression, which 
then modulates NMDA receptor activity to increase the excitatory amino acids glutamate and 
aspartate, supporting the involvement of a central mechanism in the pathophysiology of FM 
(Reyes del Paso GA et al, 2011) (Figure 1). 
As for windup phenomenon (iv), it is known to describe the changes that occur after ongoing 
painful input resulting in increased excitability of dorsal horn neurons, enhanced 
responsiveness to painful and non-painful input, and an increase in spontaneous activity 
(Staud R et al, 2004). This phenomenon is a normal occurrence to painful stimuli, but FM 
patients demonstrate enhanced windup with a greater degree of neuronal excitability and 
prolonged aftersensations (Staud R, 2007). This means that WDR neurons have a lower firing 
threshold and take longer to resolve following cessation of the stimuli.  
Concerning hyperalgesia (v), Alonso-Blanco et al conducted a study focusing on local and 
referred pain from active myofascial trigger points (MTrPs). They demonstrated that this kind 
of pain fully reproduced the overall spontaneous clinical pain area in patients with FM and 
that widespread mechanical pain hypersensitivity was related to a greater number of active 
MTrPs, suggesting that nociceptive inputs from active MTrPs may contribute to central 
sensitization in FM (Alonso-Blanco C, et al 2011). 
Because peripheral sensitization manifests only at the pain locus, whereas central 
sensitization is detected in healthy tissue distant from the pain locus, it is possible to conclude 
that hypersensitivity, not localized to the area of injury, indicates underlying changes in the 
CNS that might be explained by central sensitization (Kindler LL et al, 2011). Thus, central 
sensitization can be seen as the expression of neuroplasticity, rendering central pain a type of 
neuropathic pain, which in fact respond to the treatment with anticonvulsant drugs indicated 
for pain of neuropathic origin, such as pregabalin and gabapentin (Crofford L et al, 2005). 
Nevertheless, central sensitization alone could not be the only responsible for FM pain and 
related manifestations occurrence; also the involvement of peripheral tissue nociception 
should be supported. Indeed, results of studies analyzing neural mechanisms of somatic 
hyperalgesia suggest that FM pain is associated with widespread primary and secondary 
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cutaneous hyperalgesia, which are dynamically maintained by tonic impulse input from deep 
tissues and likely by brain-to-spinal cord facilitation. Thus FM pain is likely to be at least 
partially maintained by peripheral impulse input from deep tissues. This conclusion is also 
supported by results of several studies showing that injection of local anesthetics into painful 
muscles normalizes somatic hyperalgesia in FM patients (Staud R, 2010). 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A) In the classical model of acute pain, painful stimuli are transmitted from the 
periphery to the dorsal horn via primary afferent fibers (α-δ and C nerve fibers) and from the 
dorsal horn to the brain via the spinothalamic tract. (B) In the dorsal horn, incoming afferent 
pain signals cause the release of substance P and excitatory amino acids (EAAs), which bind 
to activate postsynaptic receptors on the pain transmission neurons (PTNs). Glia are present 
but quiescent. (C) The intense or prolonged exposure to painful stimuli causes an increasing 
in incoming afferent signals, and enhances presynaptic release of substance P and EAAs. An 
influx of Ca
2+
 increases the production of NO, which diffuses out of the neuron, making it 
hyperexcitable and further enhancing the presynaptic release of EAAs and substance P. The 
activation of glia causes the release of substances (e.g., nitric oxide, reactive oxygen species, 
prostaglandins, proinflammatory cytokines, NGF) that further increase presynaptic release 
and postsynaptic hyperexcitability. (5-HT = serotonin; NE = norepinephrine; NMDA = 
Nmethyl- D-aspartic acid; AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid; NK-1 = neurokinin; cNOS = constitutive nitric oxide synthase; NO = nitric oxide) 
(From Bradley LA, 2009). 
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2. Chronic Fatigue Syndrome 
Chronic Fatigue Syndrome (CFS) patients report a plethora of symptoms, summarized as 
follows: persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disorders, and 
subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by 
ongoing exertion, are not relieved by rest and result in a substantial reduction of previous 
levels of occupational, educational, social, or personal activities. A somewhat unusual 
secondary symptom, considered a key illness characteristic by some prominent researchers 
(e.g., Hawk C et al, 2006), is postexertional malaise (PEM) lasting at least 24 hours. PEM 
refers to sustained symptom flare-ups after routine physical or mental activities, such as 
housework, brief walks, or even reading for short periods. These postexertional symptoms 
may be delayed by as much as 24 hours or more after the triggering activity (Yoshiuchi K et 
al, 2007).  
This syndrome principally affects young women (male/female ratio ¼; age between 30-40) 
(Jason LA et al, 1999; Steele L et al, 1998). Minor alterations of immune, neuroendocrine and 
autonomic function may be associated with this syndrome. A considerably larger illness 
category, unexplained chronic fatigue (UCF), is also defined by 6 months of unexplained 
debilitating fatigue but without the requirement of additional symptoms (Sharpe M et al, 
1997). In both clinical conditions (UCF and CFS), the fatigue symptoms are medically 
“unexplained”, which indicates that they are not primarily attributable to identifiable medical 
conditions, such as untreated thyroid illness, anemia, severe sleep apnea, or morbid obesity. 
Six to thirteen percent of the population is estimated to have UCF (Ranjith G, 2005). 
Although the case definitions of CFS and FM appear quite different, these illnesses show 
considerable overlap in symptoms: 30-70% of patients with CFS also meet diagnostic criteria 
for FM and vice versa (Goshorn RK, 1998; Fukuda K et al, 1994). In this regards, the 20-70 
% of FM patients has been esteemed to also meet CFS diagnostic criteria and that the 35-70% 
of CFS patients also fulfills the FM ones (Aaron LA et al, 2000). 
  
17 
 
 
3. Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is the most frequent form of chronic inflammatory arthritis, with 
a prevalence of 0.5–1% in the adult world population (Kvien, 2004). Despite intense research 
and great advances in patient management and therapy development in recent years, still little 
is known about the underlying pathogenesis and etiology of the disease.  
RA is commonly defined as a systemic autoimmune disease mainly characterized by an 
autoimmune attack of the synovial membrane of joints, but extra-articular tissues also can be 
affected. The identity of the autoantigens that are targeted by this autoimmune response 
remains elusive. Autoreactive T cells, as well as B type ones, are thought to play a role in the 
aberrant immune response; both cell types have in the past been analyzed for the 
identification of autoantigen targets in RA. Up until now, most candidate RA autoantigens 
have been identified by analysis of autoantibodies and B cells in RA patients. Such research 
has provided evidence for the presence of numerous antibody specificities in RA (Blass S et 
al, 1999). Joint-specific as well as non-joint-specific, ubiquitous, and non-self RA antigenic 
targets have been reported in previous studies (Mewar D and Wilson AG, 2006; van Boekel 
MA et al, 2002; Magalhaes RP et al, 2002). Unfortunately, none of the previously identified 
antigenic targets can fully explain the etiology and pathogenesis of RA. Of consequence, the 
diagnosis of RA, currently based on ACR classification criteria of 1987 (Arnett FC et al, 
1988) or based on the ACR/EULAR revised criteria of 2010 (Aletaha D et al, 2010), depends 
primarily on clinical manifestations. The only serologic tests routinely used in RA assessment 
are the determinations of rheumatoid factor (RF) and anti-citrullinated peptides antibodies 
(ACPA). RF can be detected in 60–80% of RA patients. However, its specificity is limited 
because RF is also detected in other diseases, such as connective tissue diseases, Sjögren 
syndrome, chronic infections, and malignancy, as well as in healthy individuals (Somers K et 
al, 2009). More recently ACPA, which bind antigenic determinants containing the unusual 
amino acid citrulline, emerged as sensitive and specific serological markers of rheumatoid 
arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the 
laboratory diagnostics of RA. Several studies have described the occurrence of anti-CCP in 
41–68% of patients with early RA. However, up to 90% of anti-CCP positive patients were 
also positive for RF and co-occurrence of both antibodies was not more specific for RA than 
occurrence of either antibody alone (Nell VP et al, 2005).  
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Therefore, FM and RA are both rheumatic diseases of unknown etiology, but with different 
pathogenetic mechanisms, which however are mainly characterized by chronic pain. That in 
fact could be the reason why a higher prevalence of patients with RA (12.2 – 19.8%) also 
developed a FM syndrome. Indeed, as early as 1983, Wolfe and Cathey recognized the 
concomitant occurrence of FM among RA patients, observing that many features of FM 
syndrome (e.g. pain at multiple sites, fatigue, a feeling of malaise and tenderness at multiple 
spots, including joint areas) may also be present in RA itself (Yunus MB, 2012). 
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4. Brain-derived neurotrophic factor 
Brain-derived neurotrophic factor (BDNF) is an endogenous protein of 14 kDa belonging - 
together with NGF, and neurotrophins (NT) 3 and 4/5 - to the family of neurotrophic factors. 
It is known to be involved in neuronal survival and synaptic plasticity of the central and 
peripheral nervous system (CNS and PNS). Several lines of evidence converged to indicate 
that BDNF also participates in structural and functional plasticity of nociceptive pathways in 
the CNS and within the dorsal root ganglia and spinal cord. Moreover, release of BDNF 
appears to modulate or even mediate nociceptive sensory inputs and pain hypersensitivity. 
The gene encoding for BDNF is induced by cortical neurons and it is necessary for survival of 
striatal neurons in the brain (Mattson MP et al, 2004; Laske C et al, 2007). Expression of this 
gene is reduced in both Alzheimer's and Huntington disease patients (Zhang H et al, 2006; 
Zuccato C et al, 2007). 
4.1. Biosynthesis  
BDNF is produced as a 32-kDa precursor (pro-BDNF) that undergoes N-glycosylation and 
glycosulfation on residues located within the pro-domain region. N-terminal cleavage of the 
precursor generates mature BDNF as well as a minor truncated form of the precursor (28 kDa) 
that arises by a different processing mechanism than mature BDNF. Data also demonstrate 
that pro-BDNF could be biologically active, as determined by its ability to promote TrkB 
autophosphorylation. Because biosynthesis of neurotrophins normally occurs at low levels in 
neurons and non-neuronal cells, it is impossible to analyze endogenous neurotrophin 
processing with currently available techniques. Therefore, Mowla S.J. and colleagues used a 
vaccinia virus expression system to overexpress pro-BDNF and to study its processing in a 
variety of cell lines as well as in primary cultures of mouse hippocampal neurons. They 
observed a significant amount of unprocessed pro-BDNF being released into conditioned 
medium by AtT-20 cells and hippocampal neurons, cells that can release proteins both by the 
regulated and constitutive secretory pathways (Mowla SJ et al, 1999). 
Recent data show that cells with a regulated secretory pathway, including central nervous 
system neurons, release mature (i.e. fully processed) NGF (Mowla SJ et al, 1999) and NT-3 
(Farhadi HF et al, 2000) via the constitutive secretory pathway, whereas mature BDNF is 
packaged in vesicles and released through the regulated pathway (Mowla SJ et al, 1999). 
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Furthermore, BDNF is contained in a microvesicular fraction of lysed brain synaptosomes 
consistent with its anterograde transport in large dense core vesicles (Fawcett JP et al, 1997; 
von Bartheld CS et al,. 1996). 
4.2. BDNF-mediated neurotransmission: evidence from animal models 
In the sensory system BDNF is produced by a subset of primary sensory neurons 
(nociceptors) that respond to tissue injury. The cell bodies of these bipolar neurons are located 
in the dorsal root ganglia (DRG) where BDNF is synthesized and packaged in large dense-
core vesicles.  
BDNF is then transported anterogradely to the central terminals of sensory neurons in the 
dorsal horn where it can be released and activate its receptors. Concerning receptors, it is 
important to highlight that neurotrophins interact with two cell-surface receptors, the low 
affinity p75 receptor and the high-affinity tyrosine kinase receptors (trk). Whereas all 
neurotrophins bind the p75 receptor with similar affinity, the other receptors are bound with 
different affinity by each family member, as shown in Figure 3. Indeed NGF shows higher 
affinity for trkA receptors, while BDNF - as well as neurotrophin 4/5 - preferentially binds 
trkB, and NT-3 binds both trkC and, although to a lesser extent, trkA receptors. BDNF is 
produced at presynaptic level (in the cell bodies of sensory neurones that project into the 
dorsal horn) and at the level of postsynaptic dendrites (within the hippocampus); the 
activation of trkB that occurs in both types of synapse gives rise to glutamate releasing, with 
consequent potentiation of glutamatergic transmission (Malcangio M et al, 2003). 
 
 
 
 
 
 
Figure 3 Neurotrophic factors and their receptors 
In 2002 Pezet and colleagues (Pezet S et al, 2002) reviewed the literature concerning 
BDNF neurotransmission on in vitro preparations and animal models, providing the evidence 
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that antagonism of BDNF attenuates the second phase of hyperalgesia induced by formalin (in 
nerve growth factor-treated animals) and the thermal hyperalgesia induced by carageenan. By 
electrically stimulating isolated dorsal horn-with dorsal roots following different protocols 
(continuous, titanic or burst/capsaicin stimulations), as illustrated in figure 4, they showed 
that BDNF release from sensory neurons could be evoked only by burst stimuli at C-fibre 
intensity of stimulation or by capsaicin superfusion of dorsal horn slices isolated in vitro. 
Thus they concluded that BDNF is involved in some aspects of central sensitization, 
particularly in conditions of peripheral inflammation.  
 
Figure 4 Glutamate, SP and BDNF are released from nociceptors to activate second order 
dorsal horn neurons. Distinctive firing patterns of primary afferents encode the release of 
different transmitters and subsequent neuronal activation in the spinal dorsal horn. Continuous 
stimulation (CS) leads to the activation of NK and AMPA receptors on post-synaptic neurons. 
Tetanic stimulation (TS) recruits AMPA, NMDA, NK receptors. After burst stimulation (BS) 
or capsaicin treatment, in addition to NK, AMPA and NMDA receptors, TrkB receptors are 
recruited due to BDNF release. This leads to down-stream phosphorylation of ERK and 
transcription of c-fos (from Pezet S et al, 2002) 
As illustrated in figure 4, also the enhancement of N-methyl-D-aspartate (NMDA)-evoked 
responses could represent a mechanism of hyperalgesia (Staud R, 2004): indeed the 
phosphorylation on subunits 1 and 2B increases the probability that these channels are in an 
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open state (Chen L et al, 1992; Sarchielli P et al, 2002). This mechanism is clearly 
demonstrated in animal models of hyperalgesia and pain. The factors leading to this altered 
state of phosphorylation, however, are not clear. There is compelling evidence from another 
area of the CNS, the hippocampus, that BDNF is a modulator of central neuronal activity, 
since the activity-dependent release of BDNF is related to the expression of hippocampal 
long-term potentiation (LTP). LTP is defined as a characteristic activity-dependent increase in 
synaptic potency within the CNS (Kang H et al, 1995), and several evidence now suggest that 
BDNF may play a role in the spinal cord similar to that in the hippocampus; as BDNF high-
affinity to trk-B receptors induces long-term potentiation at hippocampal synapses, which are 
involved in learning and memory, it is possible that a similar phenomenon can occur also at 
the first pain synapse, between primary sensory neurons and dorsal horn neurons (see Figures 
5 and 6). 
 
 
 
 
 
 
 
 
Figure 5 Long term potentiation BDNF-mediated within hippocampus 
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Figure 6 (a) Long term potentiation (LTP) BDNF-mediated at hippocampal level, and (b) 
theoretical mechanisms of LTP-like phenomena BDNF-mediated induction within the dorsal 
horn. 
4.3. BDNF levels in plasma, serum and platelets 
The first evidence for the presence of BDNF in human serum and plasma emerged a 
decade ago (Rosenfeld RD et al, 1995). The average serum BDNF levels are known to be 
more than 100-fold higher than the plasma BDNF levels (Radka SF et al, 1996) and this 
difference is due to the degranulation of platelets during clotting process (Fujimura H et al, 
2002). Indeed, human platelets contain large amounts of BDNF (Pliego RF et al, 1997; 
Yamamoto H et al, 1990) and it has been also demonstrated that the amount of BDNF in 
serum is similar to that in washed platelet lysates (Fujimura H et al, 2002). Thus, the 
difference between serum and plasma BDNF levels appear to reflect the quantity of BDNF 
stored in circulating platelets.  
Activation of platelets may contribute to nociceptor excitation and pain, since platelets 
store and, upon stimulation, release potential algogenic substances such as serotonin, 
histamine, precursor molecules of bradykinin and BDNF (Ringkamp M et al, 1994). Since 
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platelets are a major source of BDNF in serum, it may be reasonable to assume that platelets 
are also activated in fibromyalgia, which could explain the significant increase of BDNF 
serum concentration in these patients. 
The cellular sources of BDNF in human plasma have not yet been clearly defined. Potential 
sources of BDNF are vascular endothelial and smooth muscle cells (Nakahashi T et al, 2000; 
Donovan MJ et al, 1995), in addition to activated macrophages or lymphocytes (Braun A et 
al, 1992; Kerschensteiner M et al, 1999). Moreover, there is experimental evidence that 
BDNF can cross the blood-brain barrier (Poduslo JF et al, 1996; Pan W et al, 1998) and a 
pre-clinical study found a positive correlation between serum and cortical BDNF levels 
(Karege F et al, 2002a). According to these results, BDNF changes within the CNS may be 
the expression of BDNF changes within plasma and serum. Nevertheless, data suggest that 
the majority of BDNF in plasma and serum may be of peripheral origin. 
4.4. BDNF and cytokines 
Blood levels of the cytokines interleukin (IL)-6 and IL-8 are increased in FM patients 
(Wallace DJ et al, 2001). Schulte-Herbruggen et al. suggest that BDNF secretion by 
monocytes can be specifically enhanced by IL-6 and TNFa. Since there is only a slight up 
regulation of BDNF mRNA in these cells after TNF-a or IL-6, researchers presume that the 
increase of BDNF in supernatants is based also on a release of preformed BDNF in 
monocytes (Schulte-Herbruggen et al, 2005). As IL-6 induces hyperalgesia, fatigue and 
depression, and IL-8 promotes sympathetic pain, it may be supported that they play a role in 
the etiopathogenesis of FM and in modulating FM symptoms (Laske et al., 2007). 
4.5. BDNF, depression and antidepressants  
Beyond the relationship between stress and BDNF, changes in neurotrophins and BDNF in 
depression have been a focus of interest. In addition to the monoamine theory of depression, 
Popoli and colleague (Popoli M et al, 2002) suggest that intracellular pathways have a major 
role in regulating neuroplasticity and neurodegeneration in the etiology of mood disorders. 
According to this hypothesis, stress results in neuronal atrophy and decreased neurogenesis, 
and then depression occurs. By stimulating intracellular pathways, antidepressants lead to up-
regulation of the cAMP response element binding (CREB) protein and to an increase in the 
expression of neurotrophic factors, particularly BDNF. This hypothesis was the precursor of a 
new understanding of the etiology of depression and has been the inspiration for many 
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subsequent studies, which reported low serum levels of BDNF in patients with major 
depressive disorder (MDD) not treated with antidepressants, when compared with patients 
treated or with control subjects, as well as a negative correlation between the severity of 
depression or Hamilton Depression Rating Scale (HAM-D) score and serum BDNF level 
(Karege F et al, 2002; Shimizu E et al, 2003; Huang TL et al, 2008).  
Since low-level serum BDNF in MDD is reported, it is suggested that some 
polymorphisms of the BDNF gene may be significant. Particularly, studies on Val66Met 
polymorphism of the BDNF gene – that is the most studied polymorphism and has the largest 
body of data- sought to identify the relationship between BDNF and stress-related mood 
disorders. It is suggested that healthy controls with the met allele have poor performance in 
episodic memory and that the Val66Met allele of BDNF is associated with decreased 
hippocampal volume, possible morphological anomalies in the frontal, parietal, and temporal 
cortexes, and increased activation of the hippocampus during learning and memory tasks in 
normal volunteers (Egan MF et al, 2003; Frodl T, 2007; Eker Ç et al, 2005; Post RM, 2007). 
Nevertheless, in 2 larger studies no significant difference was observed between patients with 
MDD and healthy controls, in terms of Val66Met polymorphism (Hong CJ et al, 2003; Tsai 
SJ et al, 2003). However, in a study on citalopram, even though there was no difference 
between depressed patients and healthy controls, in terms of polymorphism, Met-BDNF allele 
carriers had better responses to antidepressant treatment (Choi MJ et al, 2006). 
 Therefore, even though BDNF polymorphism does not consistently discriminate between 
depressed patients and healthy controls, it can surely discriminate between some clinical and 
therapeutical features of depression. Indeed several studies (Gönül AS et al, 2003; Aydemir Ö 
et al, 2005) showed that antidepressant treatment, while leading to MDD remission,  
significantly increased serum BDNF level, reaching levels that were comparable to the ones 
found in healthy subjects. Furthermore, two meta-analyses (Sen S et al, 2008; Brunoni AR et 
al, 2008) highlighted that serum BDNF level, significantly lower in patients with MDD than 
in healthy controls, was increased by antidepressant treatment. In particular, Brunoni et al. 
suggested in their meta-analysis that the level of serum BDNF is associated with clinical 
changes in depression and that improvement after treatment is due to change in 
neuroplasticity. As clinical improvement obtained with antidepressant treatment persists, the 
level of serum BDNF remains unchanged. A 1-year follow-up study reported that while after 
the first month of treatment patients’ plasma BDNF levels did not differ significantly from 
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those observed in healthy control subjects, serum BDNF levels in patients remained 
significantly high at all times (Piccinni A et al, 2008). 
4.6. BDNF and Fibromyalgia 
In a recent study by Laske and colleagues (Laske C et al., 2007), serum BDNF levels of 
FM patients were statistically higher compared to healthy controls and, unexpectedly, the 
comparison of BDNF levels between FM patients with and without recurrent major 
depression, as well as with or without antidepressant medications in low analgesic doses, 
revealed no statistically significant differences. This finding indicates that BDNF serum 
concentrations in FM patients are independent of pre-existing MDD or antidepressant low 
dose medication. In addition, none of the FM patients and control subjects included in the 
study had a clinically relevant depressive episode. More recently similar results were also 
reported on FM plasma samples by Haas and colleagues (Haas L et al, 2010).  
In order to deepen BDNF involvement in chronic pain conditions and hyperalgesia, several 
studies and reviews investigated and speculated on the relation between FM and chronic 
migraine (CM) (Sarchielli P et al, 2007; Sarchielli P et al, 2002; Sarchielli P et al, 2007 
Review; Malcangio M et al, 2003). Indeed, from a pathophysiological point of view, chronic 
migraine and fibromyalgia are both considered the consequence of a tonic state of increased 
excitability, in which neuroplastic changes within spinal horn neurons (as previously 
described) and the trigeminal nucleus caudalis respectively occur. Baranauskas and colleagues 
suggested that supraspinal structures, involved in pain processing, could result in spontaneous 
pain due to a reduced threshold for activation (Baranauskas G et al, 1998; Staud R, 2004). 
Researchers also speculated that this specific type of synaptic plasticity can mediate the 
maintenance of pain in both CM and FM (Malcangio M et al, 2003). Indeed, in a first study 
concerning chronic daily headache, a significant correlation emerged between the cerebro-
spinal fluid (CSF) levels of NGF, BDNF, and glutamate, suggesting the putative intervention 
of both neurotrophins in enhancing glutamatergic transmission underlying chronic 
sensitization (Sarchielli P et al, 2002). In a second study from the same research group, 
significantly higher levels of BDNF and NGF were found in the CSF of FM (p<0.001, 
p<0.001) and chronic migraine (CM) patients (p <0.0001, p<0.0005), compared with control 
subjects. No correlation was found, however, between NGF and BDNF levels as well as 
glutamate levels, and VAS values and pain intensity, pain threshold, and tender point number 
examinations both in patients with CM and FM (Sarchielli P et al, 2007). 
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4.7. BDNF and Rheumatoid Arthritis 
A number of in vitro and also in vivo studies have suggested that neurotrophins are also 
involved in arthritic processes (Manni L et al, 2003; Aloe L et al, 1992); BDNF is reported to 
be implicated in inflammatory reactions (Toma H et al, 2002; Kerschensteiner M et al 1999), 
and its production is increased in response to pro-inflammatory cytokines (Jornot L et al, 
2007). Interleukin-6 and tumour necrosis factor-alpha (TNFα) in particular enhance BDNF 
secretion by human peripheral blood monocytes (Schulte-Herbruggen O et al, 2005). Thus, 
one possibility is that the effects of these pro inflammatory cytokines in arthritic processes 
could be mediated by modulating synthesis of BDNF. Although information concerning the 
importance of BDNF in joints, including arthritic joints, is sparse, it has been shown that 
BDNF is detectable in human synovial fluid (Rihl M et al, 2005), that macrophages and 
fibroblasts in synovial tissue from patients with RA stain positively for BDNF (Weidler C et 
al, 2005) and that BDNF mRNA was found in the inflammatory synovium in two samples of 
RA patients (Rihl M et al, 2005). BDNF, apart from being synthesized in inflammatory cells, 
fibroblasts and various other cell types (for a review see Nockher WA and Renz H, 2005), is 
also a neurotransmitter (Pezet S et al, 2002). Therefore, an alternate possibility is that the 
major role of BDNF in joints is related to influences via the nervous system. Such a 
suggestion is supported by the interpretation that neurotrophins may show survival-
promoting, healing and protective effects on neurons (Patapoutian A and Reichardt LF, 
2001). Indeed, neurotrophic factors have been associated with neuroprotective roles in, e.g., 
brain lesions (Kerschensteiner M et al 1999) and inflamed gut tissue (Reinshagen M et al, 
2000). 
Whether or not BDNF is expressed in the nerve structures of joints is unknown. Several 
lines of evidence favor an effect of anti-TNFα treatment on nerve structures. It has been 
shown that infliximab, one of the most commonly prescribed anti-TNFα, attenuates the BDNF 
levels in the dorsal root ganglion and spinal cord in a rat model of herniated nucleus pulposus 
(Onda A et al, 2004) and that injection of infliximab seemed to prevent hyperalgesia that is 
caused by a combination of disk incision and nerve displacement (Murata Y et al, 2005).  
A study by Grimsholm and colleagues (Grimsholm O et al, 2008) showed that baseline 
levels for BDNF in plasma from RA patients were clearly higher compared with those of 
healthy controls. Following anti-TNF treatment, there was a decrease in BDNF levels in 
plasma. Thus, blocking the pluripotent cytokine TNFα had an influence on circulating levels 
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of BDNF. This finding was supported in part by a previous preliminary report (Del Porto F et 
al 2006) in which it was shown that the plasma levels of BDNF decreased, but not 
significantly. 
Based on these observations, one speculative suggestion may be that anti-TNF treatment, 
apart from having effects on circulating and local cells such as fibroblasts, has an effect on the 
expression of BDNF not only centrally in the nervous system (Onda A et al, 2004), but also in 
joint nerves, as a mechanism for pain relief. It may be that BDNF is not only related to 
neuroprotective but also pain-mediating effects; it is indeed a well-known fact that the nerves 
of joints become sensitized during inflammation (McDougall JJ, 2006).  
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Chapter 2 
 
Objectives 
 
The principal aim of the present PhD thesis project was to investigate BDNF-mediated 
neuroplasticity, by detecting BDNF levels in FM patients, and therefore by comparing these 
levels to the ones found in CFS, RA and healthy volunteers.  
Secondary objectives were: (i) the relation between BDNF levels and clinical variables, 
including neurocognitive disorders, which were assessed in FM and CFS patients by means of 
a computerized system; (ii) the relation between BDNF levels and psychiatric comorbidity in 
FM and CFS patients; (iii) the relation between BDNF levels and inflammatory status in RA 
patients; (iv) serum and plasmatic BDNF levels in a subgroup of FM patients before, 
immediately after, and 3-months after thermal treatments. 
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Chapter 3 
Materials and Methods 
Sixty-eight patients affected by FM, together with 45 patients with CFS, 46 with RA and 
40 healthy controls, were recruited at the Rheumatology Division of Santa Chiara Hospital 
(University of Pisa), from March 2010 to January 2012. On each participants’ group the 
following evaluations were performed.  
Clinical parameters 
 FM group (Study A and Study B): Patients recruited (n=68) already had a FM 
diagnosis according to ACR criteria of 1990 (Wolfe F et al, 1990). As established by 
the clinical practice, a rheumatologic visit, including Tender Points (TP) count, and a 
psychiatric interview - the Structured Clinical Interview (SCID) according to DSM-
IV- were conducted. Patients were also asked to complete the Fibromyalgia Impact 
Questionnaire (FIQ), the Functional Assessment of Chronic Illness Therapy-Fatigue 
Scale (FACIT), the Health Assessment Questionnaire (HAQ), the Medical Outcomes 
Study 36-Item Short Form Health Survey (SF-36), the Self-raiting anxiety scale and 
the Self-raiting depression scale (SAS and SDS respectively). Finally, another 
subgroup of 40 patients also performed the CNS vital signs
®
 neurocognitive test 
battery (Gualtieri CT et al, 2006). 
 CFS group: Patients recruited (n=45) already had a CFS diagnosis according to 
Fukuda criteria of 1994 (Fukuda K et al, 1994). As established by the clinical practice, 
a rheumatologic visit, including Tender Points (TP) count, and a psychiatric interview 
(SCID) were conducted. Like FM, also CFS patients completed FIQ, FACIT, HAQ, 
SF-36, SAS, and SDS questionnaires. Moreover, all the patients performed the CNS 
vital signs
®
 neurocognitive test battery (Gualtieri CT et al, 2006).  
 RA group: Patients recruited (n=46) already had a RA diagnosis according to ACR 
classification criteria of 1987 (Arnett FC et al, 1988). We only selected patients 
without psychiatric comorbidity (no use of substances active on the CNS was 
allowed), who also had never assumed biotechnological drugs (biologics-naïve 
patients), such as rituximab, anti-TNFα inhibitors, abatacept, tocilizumab, and any 
other experimental drug, in order to eliminate a possible confounder; only disease-
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modifying antirheumatic drugs (DMARDs), i.e. steroids -e.g. 6-metylprednisolone 
(6MP)-, leflunomide, methotrexate, hydroxyclorochine and few others, were allowed. 
As established by the clinical practice, a rheumatologic visit, which included the joint 
assessment and calculation of the Disease Activity Score on 28 joints (DAS28), was 
performed. In order to calculate the DAS28 score, patients were also asked to refer 
their general health status (GH, on a 0-100 visual analogical scale, were 100 is the 
worse ever experienced health status). 
 Health control (HC) group: 40 healthy volunteers were recruited among the 
people working at the Rheumatology Division, excluding everybody who was taking 
drugs acting on the CNS, and who had any disease diagnosed.  
Blood parameters 
All patients and controls were subjected to blood sampling to evaluate serum BDNF levels. In 
each group the following blood tests were also performed, according to the good clinical 
practice:  
 FM (Study A) and CFS groups:  
1. cytokines (IL2, IL6, IL8, IL10, TNFα and INFγ) 
2. cortisol 
3. growth hormone (GH) 
4. serotonin (5HT) 
5. adrenocorticotropic hormone (ACTH) 
 FM (Study B) group:  
- BDNF plasmatic levels 
 RA group:  
1. erythrosedimentation rate (ESR) 
2. C-reactive protein (CRP) 
3. rheumatoid factor (RF) - IgM, IgA and IgG isotypes 
4. anti-citrullinated peptide antibodies (ACPA) 
Study B overview 
Title: “Serum and plasmatic BDNF levels in patients affected by Fibromyalgia in 
treatment with balneo- or balneo-fangotherapy”. 
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A subgroup of 28 patients included in Study A was at the same time recruited to take part 
in the Study B. This second study involved the patients’ randomization into balneo- (n=14) or 
balneo-fangotherapy (n=14), both performed at Montecatini Thermal Baths, in order to 
compare the two different treatments.  
After standard rheumatologic visit and psychiatric interview (as previously described), 
patients were subjected to T0 (baseline) blood withdrawal and they were asked to complete 
FIQ, FACIT, HAQ, SF36 questionnaires. After a cycle of 10 daily treatments (lasted two 
weeks totally) at the thermal baths, patients were asked again to perform a second visit (T1), 
which included blood withdrawal and questionnaires. Finally patients came back after 3 
months from the previous visit, repeating the same visit procedures (T2). 
BDNF levels measurement 
Blood samples were obtained by venipuncture of participants fasted, at 9.00 am. As for 
serum samples, 9 ml of blood were collected in a test tube without anticoagulant, and 
centrifuged at 2000 x g for 10 minutes. Concerning plasma, 12 ml of the blood were collected 
in tubes with EDTA anticoagulant, and then centrifuged at 200 x g for 20 minutes to obtain 
platelet-rich plasma. This was then centrifuged at 2000 x g for 15 minutes to separate platelets 
and thus obtaining platelet-poor plasma.  
For quantitative assays of BDNF in serum and plasma the kit BDNF Emax® Immunoassay 
Systems (Promega) was used. This commercial kit is based on the Enzyme-Linked 
Immunosorbent Assay (ELISA) method. Tests were performed according to the 
manufacturer‘s instructions. A 96-multiwell polystyrene plate (Nunc Maxisorp) was coated 
with 100 μl of monoclonal anti-human BDNF antibody at a dilution of 1:1000. After 
overnight incubation at 4° C and washing of the plate with Tris buffer pH 7.6, supplemented 
with 0.05% Tween-20 (TBS-Tween), we proceeded by blocking the wells with 200 μl of the 
Block and Sample 1x buffer. After 1 hour incubation at room temperature and subsequent 
washing, 100 μl of serum (diluted 1:75 with Block and Sample 1x) or plasma (pre-treated 
according to manufacturer‘s instructions1, in order to break the bond of BDNF with plasmatic 
proteins and then increasing the concentration of free circulating BDNF, and finally diluted 
1:2 with Block and Sample 1x buffer) samples were incubated together with standard BDNF 
subjected to serial dilutions, realizing a 0-500 pg/ml standard curve. After 2 hours incubation 
                                                          
1
 Plasma samples were diluted 1:4 in DPBS and then  treated with HCl 6N (to a pH of 3.0). After 15 minutes of 
incubation samples were neutralized with NaOH 3N (to a pH of 7.0-8.0). 
33 
 
under agitation (400 rpm) and after 5 washes with TBS-Tween buffer, we proceeded with the 
incubation of 100 μl primary polyclonal anti-human BDNF antibody, diluted 1:50 with Block 
and Sample 1x buffer. The plate was therefore left to incubate for 2 hours, then the sequence 
of washing was repeated and 100 μl of anti-IgG secondary antibody horseradish peroxidase-
conjugated (HRP), diluted 1:20, were added to each well. After one hour incubation and 
subsequent washing, the substrate 3.3', 5.5’-tetramethylbenzidine (TMB) was added. After 10 
minutes incubation under stirring and in the absence of light, the development of blue color 
was observed. The enzymatic reaction was thus immediately quenched by addition of 100 μl 
of HCl 1N. Finally, we proceeded with the spectrophotometric reading at 450 nm, and then to 
the calculation of the of the sample concentrations (ng/ml), by means of the standard curve. 
Measurement of RF IgM, IgG and IgA levels 
Blood samples were obtained by venipuncture of RA patients fasted, at 9.00 am. Nine ml of 
blood were collected in a test tube without anticoagulant, and centrifuged at 2000 x g for 10 
minutes to obtain serum. RF levels of IgM, IgG and IgA isotypes were measured by 
Aeskulisa Rf-AGM
®
 (Aesku Diagnostics). This commercial kit is based on a sandwich 
ELISA technique. Tests were performed according to manufacturer‘s instructions. Briefly, a 
96-well microplate, precoated with a patented specific antigen, were incubated for 30 minutes 
with RA patients serum samples diluted 1:101 with the provided buffer, together with 
standards (range 0-300 U/ml) and two controls (positive and negative). After 3 washes with 
the wash buffer provided by the kit, a ready-to-use solution consisting of a secondary 
antibody anti-IgM, IgG or IgA, conjugated with HRP, was added. After 30 minutes of 
incubation and 3 washes, TMB was added and, after 30 minutes, the reaction was stopped 
with an acid solution provided by the kit. The adsorbance was read at 450 nm and the 
concentrations (U/ml) of samples calculated by means of the standard curve. 
CNS Vital Signs
©
 
CNS Vital Signs
©
 is a computerized neurocognitive health assessment platform that 
enables the objective evaluation of cognition, by providing clinicians a valid, reliable, and 
affordable “research quality” tool. Indeed it helps to accurately measure and characterize a 
patient’s neurocognitive function based on his or her status (age, level of education, and skills 
in the use of computer) or effort. CNS Vital Signs
© 
evaluates the neurocognitive abilities, as 
described in Table 1. The software calculates a score for each neurocognitive domain, and a 
general neurocognitive index (NCI). These scores are auto‐scored using an algorithm based 
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on a normative data set of 1900+ subjects, ranging from ages 8 – 90, that represents the 
“average” score (Gualtieri CT and Johnson LG 2006). In order to compare our patients to 
healthy subjects living in more similar socio-environmental conditions than the ones provided 
by the software owners, also 20 healthy subjects performed CNS Vital Signs
©
. Since results 
from these subjects overlapped the average scores provided by the software, the statistical 
analysis was realized only taking into account the standard scores and ranges calculated by 
the software itself for FMS or CFS patients. 
The test battery lasts approximately 30 minutes. The exercises included in the software are: 
Verbal memory (VBM). Fifteen words are presented, one by one, on the screen every two 
seconds. For immediate recognition, the participant has to identify those words nested among 
fifteen new words. Then, after six more tests, there is a delayed recognition trial. This test 
measures verbal learning, memory for words, word recognition and immediate and delayed 
recall. 
Visual memory (VIM). This test is analogue to the previous, except for the fact that 
geometric figures are presented. This test measures visual learning, memory for geometric 
shapes, geometric shapes recognition, immediate and delayed recall. 
Finger tapping test (FTT). This test requires athletes to press the Space Bar with their 
right index finger as many times as they can in 10 seconds. They do this once for practice, and 
then there are three test trials. The test is repeated with the left hand. This test measures motor 
speed and fine motor control. 
Symbol Digit Coding (SDC). This test consists of serial presentations of screens, each of 
which contains a bank of eight symbols above and eight empty boxes below. The participant 
types in the number that corresponds to the symbol that is highlighted. With this test 
information processing speed, complex attention, visual‐perceptual speed and information 
processing speed are evaluated. 
Stroop test (ST). It consists of three parts. In the first part, the words RED, YELLOW, 
BLUE, and GREEN (printed in black) appear at random on the screen, and the participant 
presses the space bar as soon as the athlete sees the word. In the second part, the words RED, 
YELLOW, BLUE, and GREEN appear on the screen, printed in color. The participant is 
asked to press the space bar when the color of the word matches what the word says. In the 
third part, the words RED, YELLOW, BLUE, and GREEN appear on the screen, printed in 
color. The participant is asked to press the space bar when the color of the word does not 
match what the word says. With this test it is possible to assess executive function, simple and 
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complex reaction time, speed‐accuracy trade‐off, information processing speed and 
inhibition/disinhibition. 
Shifting Attention (SAT) test. It is a measure of ability to shift from one instruction set to 
another quickly and accurately. Participants are instructed to match geometric objects either 
by shape or by color. Three figures appear on the screen, one on top and two on the bottom. 
The top figure is either a square or a circle. The bottom figures are a square and a circle. The 
figures are either red or blue (mixed randomly). The participant is asked to match one of the 
bottom figures to the top figure. The rules change at random (i.e., match the figures by shape, 
for another, by color). This test evaluates executive function (shifting sets), reaction time, 
information processing speed, and speed‐accuracy trade‐off. 
Continuous Performance (CPT). It is a measure of vigilance or sustained attention or 
attention over time. The athlete is asked to respond to the target stimulus “B” but not to any 
other letter. The stimuli are presented at random. With this test sustained attention, choice 
reaction time, and impulsivity are measured. 
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CLINICAL 
DOMAINS 
CLINICAL DOMAIN DESCRIPTION 
Neurocognitive 
Index (NCI) 
Measure: An average score derived from the domain scores or a general 
assessment of the overall neurocognitive status of the patient.  
Relevance: Summary views tend to be most informative when evaluating a 
population, a condition category, and outcomes. 
Composite 
Memory 
Measure: How well subject can recognize, remember, and retrieve words and 
geometric figures.  
Relevance: Remembering a scheduled test, recalling an appointment, taking 
medications, and attending class. 
Verbal 
Memory 
Measure: How well subject can recognize, remember, and retrieve words. 
Relevance: Remembering a scheduled test, recalling an appointment, taking 
medications, and attending class. 
Visual 
Memory 
Measure: How well subject can recognize, remember and retrieve geometric 
figures.  
Relevance: Remembering graphic instructions, navigating, operating machines, 
recalling images, and/or remember a calendar of events. 
Processing 
Speed 
Measure: How well a subject recognizes and processes information i.e., 
perceiving, attending/responding to incoming information, motor speed, fine 
motor coordination, and visual‐perceptual ability.  
Relevance: Ability to recognize and respond/react i.e., fitness‐to-drive, occupation 
issues, possible danger/risk signs or issues with accuracy and detail. 
Executive 
Function 
Measure: How well a subject recognizes rules, categories, and manages or 
navigates rapid decision making.  
Relevance: Ability to sequence tasks and manage multiple tasks simultaneously as 
well as tracking and responding to a set of instructions. 
Psychomotor 
Speed 
Measure: How well a subject perceives, attends, responds to visual‐perceptual 
information, and performs motor speed and fine motor coordination.  
Relevance: Ability to perform simple motor skills and dexterity through cognitive 
functions i.e., use of precision instruments or tools, performing mental and 
physical coordination i.e., driving a car, playing a musical instrument. 
Reaction 
Time 
Measure: How quickly the subject can react, in milliseconds, to a simple and 
increasingly complex direction set.  
Relevance: Driving a car, attending to conversation, tracking and responding to a 
set of simple instructions, taking longer to decide what response to make. 
Complex 
Attention 
Measure: Ability to track and respond to information over lengthy periods of time 
and/or perform mental tasks requiring vigilance quickly and accurately. 
Relevance: Self‐regulation and behavioral control. 
Cognitive 
Flexibility 
Measure: How well subject is able to adapt to rapidly changing and increasingly 
complex set of directions and/or to manipulate the information. Relevance: 
Reasoning, switching tasks, decision‐making, impulse control, strategy formation, 
attending to conversation. 
Table 1 CNS Vital Signs
©
 domains and their descriptions. 
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Statistical analysis 
The statistical analysis of differences between the two groups was performed using the two-
tailed T-test. The correlations between two variables were determined by using linear 
regressions and Pearson correlations. Also a multivariate analysis was performed in order to 
adjust comparisons for independent variables (age, sex, illness duration and pain perception), 
that varied between the groups of patients. The comparison between dichotomous variables 
was performed by means of the Chi-squared test. In order to establish a coefficient of 
concordance between neurocognitive disorders complained and established by the CNS Vital 
Signs
©
, the contingency analysis was performed. Significance for the results was set at p < 
0.05. All statistical analyses were carried out using the Graph Pad Prism 5.0 and SPSS 14.0 
softwares. 
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Chapter 4 
Results 
1. BDNF levels in FM, CFS, RA patients and healthy volunteers 
Demographic and clinical characteristics 
Subject’s demographic characteristics are summarized in Table 2. The 4 groups of 
participants were statistically different for age (p<0.0001) and sex (p<0.0001) but not for race.  
Particularly, CFS patients were younger compared to FM (p<0.0001) and RA (p<0.0001), RA 
patients were older than any other group (p<0.0001 for each comparison). Female sex was 
prevalent in FM group compared to healthy control (p<0.0001) and CFS group (p<0.0001), in 
agreement with the literature (Neumann L et al, 2003; Jason LA et al, 1999). Moreover, 
illness duration was found to be longer in FM patients compared to CFS (p=0.0024) and RA 
patients (p=0.014). This is probably due to: (i) CFS patients were younger, and (ii) all RA 
patients were biologics-naïve.    
 FM CFS RA HC p 
N 68 45 46 40 - 
age (y); mean (SD) 48.4 (9.8) 37.5 (11.5) 60.2 (11.8) 40.7 (10.4) <0.0001 
gender (% women) 97.1 51.1 87.0 73.3 <0.0001 
race/ethnicity 
100% 
Caucasian 
100% 
Caucasian 
100% 
Caucasian 
100% 
Caucasian 
- 
Illness duration (y); 
mean (SD) 
10.3 (7.2) 6.1 (5.0) 6.3 (6.7) - 0.0006 
      
Table 2 Demographic and clinical characteristics (HC, healthy controls). p values here 
reported derived from ANOVA test. 
There were not significant differences in therapies assumed by FM and CFS; similar 
percentages of non-steroidal anti-inflammatory drugs (NSAIDs), antidepressants (selective 
serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and tricyclic 
compounds), benzodiazepines, muscle-relaxants, anticonvulsants at low doses for neuropathic 
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pain, opioids and steroids were found between the two groups (see also paragraph 3 of this 
chapter).  
Clearly, RA patients were assuming different therapies; in particular the 43.2% of patients 
was in treatment with low doses of 6-metylprednisolone (6MP), the 24.3% with intramuscular 
or oral methotrexate, the 18.9% with hydroxycloroquine, the 8.1% with NSAIDs, and the 
2.7% with leflunomide.    
From a psychiatric point of view, only FM and CFS patients were subjected to psychiatric 
interview. However, since no RA patient was taking psychiatric drugs and any psychiatric 
consultation has never been asked for these patients, we can affirm that in this group of 
patients psychiatric comorbidity was negligible. 
The only significant difference found between FM and CFS patients was the prevalence of 
lifetime bipolar disorder of type II (BD II) (p=0.005). However the difference did not remain 
significant considering the current disorder. Prevalence of axis-I psychiatric comorbidities in 
the two groups of patients are summarized in Table 3 (see also paragraph 3 in this chapter). 
 
LT 
 
current 
   FM CFS p FM CFS p 
N 68 45 
 
68 45 
 
GAD/PD % 33.82 20.00 0,167 5.88 6.67 0,819 
MDD % 14.71 8.89 0,531 2.94 2.22 0,715 
BD II % 1.47 17.78 0,005 0.00 2.22 0,835 
ED % 1.47 4.44 0,715 0.00 0.00 - 
OCD % 1.47 0.00 0,835 1.47 0.00 0,835 
Table 3 Prevalence of axis-I psychiatric comorbidities, assessed by SCID-I 
(DSM-IV). (GAD, generalized anxiety disorder; PD, panic disorder; MDD, 
major depressive disorder; BD II, bipolar disorder type II; ED, eating 
disorders; OCD, obsessive-compulsive disorder).   
Comparison between BDNF levels of FM, CFS and RA versus HC 
By means of univariate analysis, serum BDNF levels (concentrations shown in Table 4) were 
found statistically different among the 4 groups (p=0.0009), in particular they were higher in 
FM compared to healthy controls (HC) (p=0.012), and in CFS patients compared to healthy 
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controls (p<0.0001). No statistically significant differences were found between FM and CFS, 
and between RA and HC (see Figure 7).  
  
FM CFS RA HC 
Number of values 68 45 46 40 
Mean 9,522 9,912 9,106 7,622 
Std. Deviation 2,149 2,532 2,519 2,208 
Std. Error 0,2730 0,3774 0,4140 0,3536 
  
    Minimum 4,750 2,840 4,910 2,560 
25% Percentile 8,278 8,830 7,240 6,220 
Median 9,510 10,55 8,790 8,200 
75% Percentile 11,11 11,53 10,18 9,410 
Maximum 13,78 14,28 14,87 10,89 
  
    Lower 95% CI of mean 8,976 9,151 8,266 6,907 
Upper 95% CI of mean 10,07 10,67 9,945 8,338 
  
    
Table 4 Column statistics of serum BDNF levels (ng/ml)  
 
 
 
 
 
 
 
Figure 7 Scatter plot of serum BDNF levels (one-way ANOVA test and 
Bonferroni’s post hoc test; ***, p<0.0001; *, p<0.05).  
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Since we found that age and illness duration were different between FM and healthy controls 
group, a multivariate analysis was also performed. The p adjusted for age and sex still 
remained significant (p=0.011). 
No statistically significant difference in BDNF levels was found between patients (FM and 
CFS considered together) with a lifetime psychiatric disorder versus patients with a still active 
(current) disorder, and also versus patients who had never suffered from a psychiatric disorder 
(data not shown). 
By examining CFS from a clinical point of view, we could differentiate between CFS with 
and without overlapping FM (CFS patients who also meet FM criteria had TP number ≥ 11, 
and VAS pain score ≥ 5). CFS/FM patients had higher BDNF levels compared to CFS 
patients alone, although the difference was not statistically significant. With ANOVA 
analysis, CFS/FM had higher levels of BDNF compared to healthy controls (p<0.0001), and 
CFS difference compared to healthy controls was, however, confirmed (p=0.006), as shown in 
Figure 8. 
 
Figure 8 Scatter plot of serum BDNF levels (one-way ANOVA 
test and Bonferroni’s post hoc test): CFS divided into CFS in 
overlap with FM (CFS/FM) and pure CFS. 
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Correlations of BDNF levels with clinical parameters 
In Table 5 questionnaire scores and TP count for FM and CFS patients are summarized. 
The relation between serum BDNF and clinical parameters -such as pain, fatigue, anxiety, 
depression, health and physical and mental status- in FM and CFS patients was examined by 
using the TP number and index
2
 (for pain) and scores obtained by the questionnaires 
completed by all the patients. These questionnaires were the FIQ (for pain, fatigue, anxiety 
and depression), the FACIT for fatigue, the HAQ for the health assessment, the SAS for 
anxiety, the SDS for depression, and the SF36 for physical and mental status. The only and 
more relevant difference highlighted between FM and CFS patients was related to pain; TP 
number, TPi, and VAS pain were indeed the variables that differed the most in the two 
cohorts of patients (p<0.0001 for each item), with higher scores for FM compared to CFS.  
 FM CFS p 
N 68 45 - 
TP number 16.12 (2.89) 8.07 (7.41) <0.0001 
TPi 7.10 (1.56) 2.86 (2.71) <0.0001 
FIQ 63.59 (14.68) 55.54 (20.38) 0.018 
FACIT 27.38 (9.37) 30.48 (9.97) 0.1 
VAS pain 7.15 (2.27) 3.54 (3.01) <0.0001 
VAS fatigue 8.03 (2.29) 7.74 (2.03) 0.5 
VAS anxiety 6.11 (2.42) 5.03 (2.56) 0.026 
VAS depression 4.97 (2.78) 3.81 (3.33) 0.05 
SAS 44.63 (9.44) 41.64 (8.16) 0.134 
SDS  46.51 (8.16) 45.13 (8.44) 0.464 
HAQ 0.76 (0.44) 0.49 (0.43) 0.012 
SF36 physical status index 30.32 (6.89) 32.26 (7.26) 0.321 
SF36 mental status index 36.49 (11.87) 36.74 (11.59) 0.936 
 
Table 5 Clinical characteristics, questionnaire scores and visual analogue 
scales – mean (SD). 
 
                                                          
2
 TP index was calculated by dividing the TP total score (sum of the  0-10 scores reported by the patient for each 
TP)  for the number of positive TPs. 
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Also FIQ, VAS anxiety, VAS depression and HAQ were slightly higher in FM group than in 
CFS, probably meaning that FM patients were generally more compromised by the disease in 
from a mental (mood) and functional point of view. However no correlation was found 
between BDNF and each of the above mentioned questionnaires. 
In RA patients, BDNF levels did not correlate with the severity of disease, calculated with 
DAS28 (data not shown). 
Correlations of BDNF levels with routine blood tests 
The determined blood parameters (cytokines IL-2, IL-6, IL-8, IL-10 and TNFα; cortisol; GH; 
5HT; ACTH) were not found to correlate with BDNF levels, both in FM and CFS patients 
(taken together or separately). Only INF-γ positively correlated with BDNF levels when 
patients were considered together (r=0.34; p=0.01). 
Examining RA group, 90% of patients were RF positive (RF+). In particular, we found that 
patients with positive RF IgM and IgG isotypes had higher BDNF levels compared to RF- 
patients (p=0.03 for IgM and p=0.01 for IgG). RA patients with RF+ of all isotypes also had 
higher BDNF levels compared to healthy controls (p=0.0051 for IgA, p=0.0021 for IgG and 
p=0.0042 for IgM) (data not shown). Moreover RF IgM and RF IgG (but not IgA) were found 
to positively correlate with BDNF levels (r=0.42, p=0.0094 and r=0.42, p=0.0097 
respectively), as shown in Figure 9. 
 
 
 
 
 
 
Figure 9 Linear regression of serum BDNF levels and IgM (A) or IgG (B) RF 
levels (U/ml). 
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Furthermore, CRP was found to negatively correlate with BDNF concentrations (r=-0.33; 
p=0.04), RF+ patients had lower CRP levels (p=0.04), and patients taking 6MP had lower 
BDNF (p=0.002) but higher CRP levels (p<0.0001). Finally, 37.5% of RA FR+ patients was 
taking 6MP, versus 53.9% of RA RF- patients, although the difference did not reach the 
statistical significativity. No other difference was found between RA RF+ and RA RF- 
patients in terms of drug use, disease severity and duration (data not shown). 
 
 
 
 
 
 
 
Figure 10 Linear regression of serum BDNF levels 
(ng/ml) and CRP (mg/dl) 
 
2. BDNF levels in FM patients before and after thermal baths (Study B) 
Clinical characteristics of patients who participated to thermal treatments are summarized in 
Table 5. Fourteen out of 28 patients were randomized to balneo-therapy while the other 14 to 
balneofango-therapy. At the baseline the two groups of patients showed similar demographic 
and clinical characteristics (data not shown). 
Serum BDNF levels -measured at baseline (T0), after the treatments (T1) and 3 months after 
the end of the treatments (T2)- were found to significantly decrease at T2, as shown in Figure 
11. The same trend was not observe for plasma samples. 
No difference was observed at the baseline between patients who did balneo- and 
balneofango-therapy. Moreover, also in this subgroup of patients, at each visit, BDNF levels 
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did not correlate with illness duration, pain perception, or with other clinical scores (data not 
shown). However, at T1 VAS pain and FIQ were decreased compared to T0, although the 
difference did not reach the statistical significance (p=0.06 and p=0.08 respectively). 
  FM 
N 28 
age (y) 50.96 (8.19) 
sex 96.4% 
race % Caucasian 
TP number 16.25 (3.30) 
Tpi 7.54 (1.65) 
FIQ 64.09 (17.09) 
FACIT 27.89 (9.74) 
VAS pain 7.11 (2.31) 
VAS fatigue 8.18 (2.11) 
VAS anxiety 6.21 (2.92) 
VAS depression 5.58 (2.98) 
HAQ;  0.75 (0.45) 
SF36 physical status index 30.66 (14.42) 
SF36 mental status index 66.87 (23.07) 
Table 6 Clinical characteristics and questionnaire 
scores –mean (SD)- of patients who participated to 
Study B. 
 
Figure 11 A) Serum BDNF levels (ng/ml) at T0, T1 and T2 of thermal treatment. B) 
Plasmatic BDNF levels (ng/ml) (ANOVA analysis for repeated measures).  
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 SERUM PLASMA 
 T0 T1 T2 T0 T1 T2 
Mean 10,15 9,67 8,94 1,59 1,25 1,22 
Std. Deviation 1,90 2,27 2,19 1,83 1,24 0,99 
Std. Error 0,37 0,44 0,43 0,36 0,24 0,19 
 
      
Minimum 6,86 6,09 3,86 0,21 0,13 0,06 
25% Percentile 8,64 7,86 7,35 0,54 0,65 0,67 
Median 9,82 9,72 8,95 0,98 0,94 0,91 
75% Percentile 11,50 11,00 10,80 2,05 1,46 1,33 
Maximum 13,78 14,67 13,23 9,37 6,66 4,43 
 
      Lower 95% CI of 
mean 
9,38 8,76 8,06 0,85 0,75 0,82 
Upper 95% CI of 
mean 
10,92 10,59 9,83 2,33 1,75 1,62 
Table 7 Column statistics of serum and plasma BDNF levels (ng/ml) at T0, T1 and 
T2 of thermal treatment. 
3. Neurocognitive disorders in FM and CFS patients 
No correlation was found between BDNF serum levels and neurocognitive disorders, neither 
complained, nor assessed by means of CNS Vital Signs
© 
software. However, interesting 
results came from the analysis of CNS standard scores and the clinical parameters examined 
in the FM and CFS patients, as well as from the comparison between the two groups in terms 
of complained and real impairments. 
Demographic data  
Subject demographic characteristics of patients recruited for neurocognitive observations are 
summarized in Table 7. FM and CFS were significantly different in terms of age and sex 
(p=0,001 and p=0,0001 respectively), in accordance with the literature (Neumann L et al, 
2003; Jason LA et al, 1999). No difference was found in CFS patients between women and 
men. 
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 FM CFS p 
N 40 45 - 
gender  97.5% women 46.7% women 0.0001 
age (y); mean (SD) 46.6 (10,5) 37.5 (11.5) 0.001 
race/ethnicity 100% Caucasian 100% Caucasian - 
education (y); mean (SD) 12.7 (4.2) 14.2 (3.1) 0.062 
employment status (%)    
managerial/office 25.0 35.6 0,413 
skilled labor 12.5 15.6 0,927 
semiskilled labor 10.0 11.1 0,852 
students 2.5 15.6 0,092 
homemaker 10.0 0.0 0,097 
retired 22.5 4.4 0,031 
unemployed 17.5 17.8 0,801 
Table 8 Demographic characteristics 
 
FM and CFS patients did not differ by race, years of education and employment status (except 
for the prevalence of retired people in FM group, that depended of the higher mean age). As 
shown in table 2, more almost 18% of both FM and CFS patients was unemployed and 
referred to have left work because of the disease.  
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Clinical characterization 
Clinical characteristics, questionnaire scores and scales are shown in Table 9. 
FM patients had also a longer duration of illness compared to CFS patients (p=0.004).  
 
 FM CFS p 
illness duration (y); mean (SD) 9.8 (6,8) 6.4 (5.1) 0.004 
Tender Points;  mean (SD)    
N 16.2 (2.5) 8.1 (7.4) <0.0001 
TPi 6.8 (1.5) 2.9 (2.7) <0.0001 
FIQ;  mean (SD) 62.8 (13.3) 55.5 (20.4) 0.064 
FACIT;  mean (SD) 27.6 (8.6) 30.5 (10.0) 0.167 
VAS pain;  mean (SD) 7.1 (2.3) 3.5 (3.0) <0.0001 
VAS fatigue;  mean (SD) 8.0 (2.3) 7.6 (2.1) 0.474 
VAS anxiety 5.9 (2.0) 5.0 (2.5) 0.102 
VAS depression 4.3 (2.4) 3.8 (3.2) 0.461 
SAS;  mean (SD) 44.8 (9.5) 41.4 (8.3) 0.110 
SDS;  mean (SD)  46.5 (8.3) 44.4 (8.2) 0.465 
cognitive impairments complained (%) 85.0 75.6 0.842 
concentration yes/no (%) 80.0 73.3 0.921 
memory yes/no (%) 57.5 55.6 0.932 
Sleep disorders complained    
sleep disorder yes/no (%) 85.0 71.1 0.704 
VAS restful sleep; mean (SD) 7.7 (2.5) 7.2 (2.2) 0.368 
    
Table 9 Clinical characteristics, questionnaire scores and visual analogue scales. 
 
In agreement with the classification criteria, FM patients showed a higher number of TP and a 
higher TP index (p<0.0001). This difference is also supported by the difference found 
between patients’ VAS pain (p<0.0001). No difference between the two groups was instead 
identified with respect to fatigue, neither by means of FACIT questionnaire, nor with VAS 
fatigue. No statistically significant difference was also found for auto-referred feelings of 
anxiety and depression, which were both assessed with visual scales and questionnaires (SAS 
and SDS), as shown in Table 9. 
Concerning complained cognitive disorders, any difference was found in terms of 
concentration or/and attention between the two groups of patients. Also sleep disorders, 
referred by “yes” or “not” and through a VAS “rested/tired” upon awaking, were not 
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statistically different between FM and CFS patients. No difference was found within CFS 
group between male and female sex. 
Thus, the only variables differing between the two groups were age, sex (prevalence of 
women), duration of illness and pain perception (VAS pain and TP count).  
Pharmacological therapies 
Analyzing drug assumption, no statistically significant differences were found between FM 
and CFS patients, as shown in Table 10. Thus, differences of neurocognitive function between 
the two groups were independent of drug intake. 
Drug FM % CFS % p 
NSAIDs 15,0 8,9 0,592 
Benzodiazepines 22,5 13,3 0,411 
SSRI 20,0 15,6 0,801 
SNRI 7,5 11,1 0,844 
tricyclic antidepressants 2,5 4,4 0,917 
Opioids 10,0 0,0 0,097 
Steroids 0,0 4,4 0,527 
muscle- relaxants 22,5 11,1 0,263 
Anticonvulsants 22,5 11,1 0,263 
antidepressants* 30,0 28,9 0,9 
drugs** 57,5 44,4 0,325 
Table 10 Comparison of drug assumption between FM and CFS patients 
(NSAIDs, non steroidal anti-inflammatory drugs; SSRI, selective 
serotonin reuptake inhibitors; SNRI, serotonin noradrenalin reuptake 
inhibitors). * SSRI + SNRI + tricyclic antidepressants; ** patients who 
assumed at least one drug. 
 
Psychiatric comorbidity 
No difference was observed between FM and CFS patients in terms of axis-I psychiatric 
disorders, assessed by means of SCID-I (Table 11). The prevalent psychiatric condition in 
both groups was a lifetime (LT) disorder characterized by generalized anxiety (GAD) and 
panic attacks (PD), which was present in the 37.50% and in the 20.00% of FM and CFS 
respectively. The same condition persisted only in 1 out of 15 patients (11.10%) and in 1 out 
of 3 patients (6.67%) in the FM and CFS group respectively (current psychiatric disorder). 
Bipolar type-II disorder (BD II) was instead observed in a larger number of CFS patients 
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(17.78%) as a lifetime condition compared to FM patients (2.50%), although the difference 
was not statistically significant (p=0.086). Only one CFS patient and none of the FM patients, 
still had a BD II disorder at the observation time. Small percentages of patients from both 
groups resulted to have psychiatric LT or current disorders such as the major depressive 
disorder (MDD; 10.00% LT and 5.56% current in FM versus 8.89% and 2.22% in CFS), LT 
eating disorders such as anorexia and bulimia (ED; 2.50% in FM and 4.44% in CFS), and 
current obsessive-compulsive disorder (OCD; present only in 1 FM patients, 2.50%). Thank 
to these observations we can suppose that, at least in our cohort of patients, neurocognitive 
functioning is independent of psychiatric comorbidity.  
 
LT (%) current (%) 
  FMS CFS p FMS CFS p 
GAD/PD 37.50 20.00 0,12 11,11 6.67 0,817 
MDD 10.00 8.89 0,79 5.56 2.22 0,917 
BD II 2.50 17.78 0,053 0.00 2.22 0,953 
ED 2.5 4.44 0,92 0.00 0.00 - 
OCD 2.5 0.00 0,95 2.5 0.00 0,953 
Table 11 Lifetime (LT) and current psychiatric comorbidity assessed 
by SCID-I (DSM-IV) 
 
Neurocognitive functioning assessment 
As previously shown, FM and CFS patients similarly complained about neurocognitive 
problems of concentration or/and attention. Nevertheless, through the use of CNS Vital 
Signs© test battery, FM patients resulted to have more compromised neurocognitive functions 
compared to CFS patients. Indeed the neurocognitive index (NCI) was lower in FM than in 
CFS patients (p=0.0032). The NCI of fibromyalgic patients was lower because also singular 
items such as visual memory (ViM; p=0.0039), processing speed (PrS; p=0.02), executive 
function (EF; p=0.001), psychomotor speed (PsS; p<0.0001) and cognitive flexibility (CF; 
p=0.0011) were lower in these patients compared to CFS. These results were obtained by 
means of univariate analysis (see Figure 12). Since FM and CFS patients differed in terms of 
age, sex, disease duration and pain perception (VAS pain and TPi), also multivariate analysis 
was performed in order to adjust results for all possible confounders. Mean (SD) scores from 
CNS Vital Signs
©
, p and adjusted p for age, sex, duration of illness and pain perception (VAS 
pain and TPi) are shown in Table 12. In CFS patients, no difference was found between 
female and male sex. 
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Figure 12 Comparison of CNS Vital Signs
© 
mean standard scores between FM and CFS 
patients (standard scores ranges: >110=above; 110-90 (light-green)=average; 89-80 
(yellow)=low average; 79-70 (orange)=low; <70 (red)=very low). 
 
 
FM CFS p 
adjusted 
p 
Neurocognitive index (NCI) 74,48 (21,60) 89,09 (22,65) 0.0032 0.036 
Composite memory (CM) 87,30 (18,33) 93,67 (17,13) ns ns 
Verbal memory (VeM) 88,18 (20,84) 89,09 (21,26) ns ns 
Visual memory (ViM) 91,38 (14,38) 100,5 (13,88) 0.0039 0.027 
Processing speed (PrS) 79,28 (19,88) 88,58 (16,37) 0.02 0.047 
Executive function (EF) 70,93 (33,62) 93,22 (25,20) 0.001 0.036 
Psychomotor speed (PsS) 61,85 (34,69) 89,96 (22,75) <0.0001 0.012 
Reaction time (RT) 89,83 (19,42) 94,31 (21,88) ns ns 
Complex attention (CA) 64,03 (45,55) 75,53 (74,02) ns ns 
Cognitive flexibility (CF) 69,75 (34,10) 91,98 (26,27) 0.008 0.032 
Table 12 mean CNS vital signs scores (SD). (ns, not significant). 
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Neurocognitive function correlated with the duration of illness. In particular, duration of 
illness negatively correlated with NCI (r=-0.23; p=0.034), ViM (r=-0.28; p=0.0099) and PsS 
(r=-0.45; p<0.0001) (see Figure 13 A).  
 
 
 
 
 
 
 
 
 
Figure 13 A) Negative correlation between illness duration and NCI. B) 
Negative correlation between VAS pain and NCI. 
 
Moreover, considering the two groups together, also VAS pain was found to negatively 
correlate with NCI standard score (r=-0.31; p=0.0046) and with single items of the CNS vital 
signs, such as ViM (r=-0.30; p=0.0066), PrS (r=-0.29; p=0.008), EF (r=-0.28; p=0.01), PsS 
(r=-0.30; p=0.007), and CF (r=-0.30; p=0.007) (see Figure 13 B). On the contrary, VAS 
fatigue was not found to correlate with any item of the CNS Vital Signs
©
. However, when the 
two groups were considered separately, the significant negative correlation of VAS pain and 
neurocognitive disorders was lost, both in FM and in CFS groups. This finding is probably 
due to the fact that, within each group of patients, VAS pain scores did not spread on the 
entire scale, while when patients were taken together, we could observe a wider range of VAS 
pain scores. Furthermore, while in FM patients VAS pain correlated with VAS fatigue 
(r=0.47; p=0.003;), in CFS patients did not. NCI did not correlate with any clinical 
parameters, nevertheless other correlations were found in CFS group: executive function and 
cognitive flexibility negatively correlated with FIQ (r=-0.36; p=0.016 and r=-0.318; p=0.035, 
respectively) and FACIT (r=-0.30; p=0.048 and r=-0.374; p=0.011, respectively). In FMS 
group instead ViM negatively correlated with VAS pain (r=-0.475; p=0.008) and with FIQ 
(r=-0.374; p=0.042) (data not shown). 
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Neurocognitive standard scores were also analyzed by comparing both FM and CFS patients 
with a psychiatric disorder versus those who had not. In particular, we found statistically 
significant differences between patients who had or had not a lifetime psychiatric disorder in 
terms of NCI (mean ± SD: 75.0±25.8 vs 90.3±16.8; p=0.002), PrS (mean ± SD: 80.4±19.1 vs 
88.5±17.3; p=0.043), EF (mean ± SD: 76.0±34.6 vs 90.2±25.7; p=0.036), PsS (mean ± SD: 
68.2±35.8 vs 86.3±24.3; p=0.008), CF (mean ± SD: 74.1±35.4 vs 89.9±25.7; p=0.022).  
The more impaired function in patients with a lifetime psychiatric disorder was psychomotor 
speed, whose mean standard score was well under the range of normality (very low score), 
while the other functions seemed to be less impaired. As for presence of a current psychiatric 
disorder, no difference was instead observed between patients who had and patients who had 
not. 
Further analysis showed that neurocognitive function, measured with the NCI, also differ 
between patients assuming or not antidepressants (p=0.015), particularly in terms of complex 
attention (p=0.008), which seemed to decrease well under the normality range in patients 
taking antidepressants (mean ± SD: 44.07 ± 94.81 and 82.24 ± 33.58 respectively). 
Considering instead patients under one or more pharmacological treatments versus patients 
not treated at the observation time, the only difference highlighted was related to processing 
speed (PrS), which was slightly lower in patients assuming drugs (p=0.04).  
Finally we calculated the k-coefficient of concordance between complained (subjective) and 
objective neurocognitive disorders in both group of patients. We found in both groups a lack 
of concordance between complained and real deficits, although in CFS the difference resulted 
more marked, as shown in Table 13.  
 
 
 
 
 
Table 13 Analysis of subjective versus objective 
neurocognitive disorders (NCD). 
  
  FM CFS 
NCD subjective % 85.0% 84.4% 
NCD objective % 42.5% 22.2% 
concordant 21/40 15/45 
k-coefficient  0.0082 -0.009 
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Chapter 5 
Discussion 
One of the most interesting results highlighted by this PhD thesis project was the comparison 
of BDNF levels in FM versus CFS and RA patients, and healthy controls. The literature 
concerning BDNF and FM reported elevated levels of this neurotrophin in sera, plasma, and 
cerebrospinal fluid samples (Laske et al., 2007; Haas L et al, 2010; Sarchielli P et al, 2007). 
Thus, with the present study we confirmed the data, also adding a further information: also in 
CFS patients, who also had a overlapped FM, BDNF serum levels were increased compared 
to healthy volunteers. Unexpectedly, also CFS patients presenting only with persisted fatigue, 
therefore without a musculoskeletal pain complaint, had elevated BDNF levels.  
Several questions spontaneously arise:  
 Could be chronic stressors, to which both patients are subjected, the main cause 
explaining the reason why the CNS activate its neurotransmitters (especially those 
belonging to nociceptive and neuroplasticity pathways) to cope with the threat?  
 Is BDNF-mediated neuroplasticity the biological defense weapon through which our 
system faces a chronic pain or, more generally, a chronic stressor?  
These speculation, supported by several researchers and studies (Popoli M et al, 2002; Urban 
MO and Gebhart GF, 1999; Giovengo SL et al, 1999; Pezet S et al, 2002), are also confirmed 
by the result found in FM patients who participate to thermal therapies program, whose 
BDNF serum levels, together with VAS pain and FIQ score (although these last did not reach 
the statistical significance), significantly decreased after the end of the study. Of great 
importance is the fact that only serum -and not plasmatic- BDNF decreased after the cycle of 
thermal treatments; this finding seems to suggest that BDNF stored in platelets (that is the 
peripheral amount of BDNF), and not circulating BDNF (that is the one coming from the 
CNS) is somehow involved in FM and CFS pathogenesis, as well as in RA, even if in this 
case the role of autoimmune system needs further investigations. 
Fibromyalgia and chronic fatigue syndromes are still often viewed as psychosomatic 
disorders. In the past years several authors (Raphael KG et al, 2006; Epstein SA et al, 1999; 
Ercolani M et al, 1994) has speculated that the psychiatric background of FM and CFS could 
be the main cause triggering for altered central perceptions, leading in this way to chronic 
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pain and fatigue without a clinically explainable reason. However, our results showed -and 
also confirmed previous results (Laske C et al, 2007)- that BDNF levels are independent of 
psychiatric comorbidity (assessed by SCID-I as axis-I disorders), psychiatric spectra (as 
highlighted by the lack of correlation between BDNF and SAS/SDS scales, and also with 
VAS pain and anxiety), and psychiatric drugs substances, in both syndromes. 
Also data coming from the analysis of RA group are encouraging. RA represents indeed 
another model of chronic pain, but despite FM and CFS, less subjected to psychiatric 
disorders (Walker EA et al, 1997). Particularly RA patients recruited for this study were not 
using drugs acting on CNS and were never diagnosed for a psychiatric disorder. The finding 
that RA patients positive for RF IgA, IgG and IgM had higher serum levels of BDNF, and 
that BDNF concentrations positively correlated with RF IgG and IgM U/ml, suggest a 
possible involvement of a previous inflammation status to which the system was reacting 
increasing BDNF levels. Indeed, positivity to RF, that normally coincide with a worse 
severity of disease, autoimmune activation and inflammation, is here resulted linked to higher 
BDNF levels, and probably as a consequence of this, with a decrease of CRP and thus with a 
reduced use of 6MP, which is consistent with the literature (Kerschensteiner M et al, 1999).  
The use of 6MP certainly reduces the symptoms of inflammation and pain, but have no effect 
on autoimmune dysregulation. Probably BDNF peripheral release could be interpreted as a 
continuous attempt of the system to face and reduce pain and inflammation. These 
suppositions are also reported in other several studies (Kerschensteiner M et al, 1999; 
Reinshagen M et al, 2000; Onda A et al, 2004; Murata Y et al, 2005; Grimsholm O et al, 
2008; Del Porto F et al, 2006), which found that plasma BDNF levels in RA patients were 
increased at the baseline compared to healthy control, but they get lower after anti-TNFα 
therapy. The strong point of the present study was to have excluded patients who were taking 
-or had taken- biologic drugs; this choice now allows us to reach more sustainable 
conclusions. Further investigations on larger cohort of RA patients are necessary to confirm 
our findings, and the evaluation of BDNF levels before and after the treatment with different 
biologic drugs will soon performed.    
Another important aspect highlighted by the present research, even if it is not the only and 
neither the first to deal with the subject (McCracken LM et al, 2001; Westoby CJ et al, 2009; 
Suhr JA, 2003), is the one concerning the relation between chronic pain and neurocognitive 
impairments. The fact that CNS Vital Signs
©
 standard scores did not correlate with BDNF 
levels, in any way and in any group of patients, lead us to consider them as independent 
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variables, or at least not directly influenced one by the other, although the following evidence 
seems to suggest this relationship: (i) BDNF high-affinity to trk-B receptors is known to 
induce long-term potentiation at hippocampal synapses, which are involved in learning and 
memory (Kang H et al, 1995), and (ii) in human, serum BDNF increased together with 
improvement in cognitive function after acute cycling exercise (Ferris LT et al, 2007). Thus, 
neurocognitive impairments in FM and, although to a less extent in CFS patients, are 
principally dependent of chronic pain – as resulted by the correlation of neurocognitive index 
and other CNS Vital Signs
©
 domains with VAS pain and illness duration, as well as by a 
worse impairment in FM compared to CFS patients- and, as a consequence, of central 
sensitization, even though they seem not to be linked to BDNF-mediated neuroplasticity. 
Unlike other studies (Roth RS et al, 2005; McCracken LM et al, 2001; Suhr JA, 2003), we did 
not find any correlation between neurocognitive impairment and depression, nor fatigue, 
although some neurocognitive items –in particular psychomotor speed- were lower in patients 
with a lifetime psychiatric disorder compared to patients without. Moreover, concerning the 
frequently found prevalence of neurocognitive impairments in female sex - reported by 
previously mentioned authors - our data suggested instead that in FM and CFS patients sex 
did not influence neurocognition, since the sex-adjusted analysis still remained significant, 
and no difference was highlighted by comparing male and female patients within CFS group. 
However, unlike these studies, in the present one neurocognitive functioning was assessed by 
means of computerized system, more objective and accurate in evaluate every single ability. 
Accumulating evidence now indicates that a number of chronic pain and stress-related 
disorders, including chronic low back pain, FM and CFS are characterized by gray matter 
reductions (Apkarian AV et al, 2004; de Lange FP et al, 2005; Kuchinad A et al, 2007). A 
possible explanation for the decreased gray matter density in these disorders might be atrophy 
secondary to excitotoxicity and/or exposure to inflammation-related agents, such as cytokines 
(Apkarian et al., 2004). Kuchinad and colleagues (2007) found that FMS patients have brain 
gray matter atrophy with a yearly decrease in gray matter volume more than three times than 
that of age-matched controls. Gray matter loss occurs mainly in regions related to stress 
(parahippocampal gyrus) and pain processing (cingulated, insular and prefrontal cortices). A 
recent study found that FM patients had significantly less gray matter volumes than healthy 
controls in pain-related brain areas but not gray matter changes associated with depression 
(Robinson ME et al, 2011). Structural changes in these systems could contribute to the 
maintenance of pain, while gray matter atrophy in areas such as parahippocampal and frontal 
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cortices appears consistent with cognitive deficits but also with affective disturbances 
reported in FM patients.  
We have already shown in Chapter 4 (named Results, Figure 12) how evident is the 
neurocognitive function impairment in FM patients, also compared to CFS patients who had 
instead almost all the CNV Vital Signs
©
 domains within the normal range. In particular, FM 
patients, aside from the NC index, which is only a composite index that globally indicate how 
compromised are cognitive faculties, reported very low standards score – here listed in order 
of severity- in psychomotor speed, complex attention (low also in CFS), cognitive flexibility, 
executive functioning, and processing speed (low).  
An impaired psychomotor speed involves difficulties in performing simple motor skills i.e., 
use of precision instruments or tools, performing mental and physical coordination i.e., 
driving a car, playing a musical instrument. A deficit in complex attention make instead 
problematic the performance of mental tasks that require vigilance, quickly and accurately. 
Cognitive flexibility is interpreted as the ability to adapt to rapid changes and to increasingly 
complex set of directions. Thus, an impaired cognitive flexibility can cause difficulties in 
reasoning, switching tasks, decision‐making, etc…, similar to difficulties caused by a deficit 
in executive function, which is the ability to sequence tasks and manage multiple tasks 
simultaneously, as well as tracking and responding to a set of instructions. It is not surprising 
that these two capabilities go hand in hand. Finally, processing speed, that is the ability to 
recognize and respond/react, when impaired it can causes occupational issues and difficulties 
in identifying possible danger/risk signs. 
Of great interest are the negative correlations of peculiar NC domains (EF, CF and ViM) with 
clinical parameters which typically describe the severity of both FM and CFS (FIQ, FACIT 
and VAS scales). According to these results, CFS patients who had a more severe disease 
(higher FIQ and FACIT scores) also had more impaired executive function and cognitive 
flexibility, confirming the possibility of a dysfunction at prefrontal level, as reported by 
neuroimaging studies  (MacHale SM et al, 2000). FM patients who had more severe disease 
(higher FIQ and VAS pain) reported instead poor performance in terms of visual memory, 
suggesting the possible involvement of brain areas such as medial temporal lobe and occipital 
cortex in the pathophysiology of the syndrome (Khan ZU et al, 2011). 
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Globally considering the reported findings, in FM patients attention and concentration 
generally seemed more compromised than memory. This finding could be due to chronic pain, 
as also observed by Glass (Glass JM, 2006). In particular complex attention was found 
reduced by the use of antidepressants (SSRI, SNRI and/or tricyclic compounds), as previously 
reported also by McCracken and colleagues (McCracken LM et al, 2001). Processing speed 
instead seemed to be more impaired in patients who were assuming at least one drug among 
those which are normally prescribed for the treatment of FM and CFS. Further investigations 
on the relationship between neurocognitive disorders and drugs commonly prescribed for the 
treatment of FM -and also on the link among the various affective disorders- could be useful 
to understand if the impairment of neurocognitive function could be at least partially ascribed 
to the use of some of these ones. However that fact that no difference was found in 
pharmacological therapies between FM and CFS patients let us suppose that the 
neurocognitive impairment in FM is not due to assumed drugs.  
Interestingly, the analysis between complained attention and memory disorders and objective 
neurocognitive impairment showed that, while FM patients were more compromised but less 
frequent aware of their cognition problems, CFS patients usually complained without having 
a real deficit. A possible explanation of the last observation could be related to personality 
traits of CFS patients, such as self-criticism and perfectionism (Kempke S et al, 2011), which 
can lead to excessive worries about their performance (e.g., concern over mistakes and doubt 
about actions). Since difficult to demonstrate, the reason of discrepancy between subjective 
and objective neurocognitive disorders in CFS and FM will probably remain explained only 
by mere suppositions. 
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Chapter 6 
 
Conclusions 
 
The main findings of the present PhD thesis work have been: (i) the increased BDNF 
levels in sera of patients affected by FM, CFS and RA (but only those who were positive to 
rheumatoid factor), compared to healthy volunteers; (ii) the positive correlation between 
BDNF and rheumatoid factor of IgG and IgM isotypes, and the negative one with C-reactive 
protein; (iii) the lack of correlation between BDNF and neurocognitive disorders, assessed by 
the software CNS Vital Signs©; (iv) the more elevated prevalence of neurocognitive disorders 
in FM than in CFS patients, despite the more frequent complaint of the latter; (v) the tight 
relationship between neurocognitive impairments and chronic pain, which is independent of 
psychiatric comorbidity.    
The BDNF-mediated neuroplasticity is somehow involved in the pathogenesis of FM and 
related condition, particularly in CFS, which shares with FM the symptoms of chronic pain. 
Moreover, both disease are known to be chronic stress conditions, being characterized by 
dramatic reduction of physical and mental energy, vitality, as well as neurocognitive 
performances, independent of the presence of psychiatric disorders. Thus it is likely that 
BDNF-mediated neuroplasticity in these syndromes is a protective mechanism. This 
hypothesis could explain the elevated BDNF levels found in sera -but not in plasma- samples, 
and their decrease after thermal treatment.  
Even if BDNF it is not specific for FM or chronic pain, and the difference here reported 
between BDNF levels of FM or CFS patients compared to healthy controls are not strong 
enough to use BDNF in the diagnostic field, BDNF -as also proved by this work- has 
smoothed the way to new investigations on FM, CFS and RA etiopathogenesis on one hand, 
and could turn into being a useful biomarker for FM/chronic pain therapies monitoring on the 
other. 
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